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ABSTRACT 
 
 Purinergic receptors respond to extracellular nucleotides and their metabolites. 
They act as important signaling transduction molecules in a variety of biological 
processes and are important in a number of pathophysiologic conditions that impact 
human health. A subset of these receptors acts as non-selective cation channels, 
designated as P2X receptors, which can induce electrical activities in the cellular 
membrane and thus impact cellular function. A number of longitudinal studies following 
surgically or genetically induced heart failure animals have demonstrated potential 
improvement of cardiac function with P2X4 receptor overexpression. We explore here 
how P2X signaling affects cardiomyocyte excitability and leads to changes in 
contraction in both computational and experimental models. We confirm computational 
predictions of P2X induced membrane depolarization and subsequent changes in a 
number of cardiomyocyte currents using whole cell patch clamp techniques. Direct 
sodium cxxxentry via P2X channels leading to intracellular ion concentration changes 
were detected with an increase in Na+-K+ ATPase peak current and enhancement of the 
calcium entry mode of the Na+-Ca2+ exchanger. The latter we show may play a role in 
the enhancement of contractile response by extracellular ATP. With the aid of 
computational prediction and interpretation, our findings highlight the value of dynamic 
considerations of channel currents and offer explanations for prior inconsistencies in the 
purinergic field. Moreover, we establish an interaction between the P2X4 receptor and 
nitric oxide production that may underlie its cardioprotective effects after myocardial 
injury. This improved understanding of P2X action on the heart helps to improve our 
evaluation of its targeting in clinical applications.   
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 Chapter 1 
Introductiona 
The human heart is an amazingly efficient biological pump. It can adjust to a wide range 
of situations, providing blood flow to our bodies while we rest or exercise strenuously; and it 
works relentlessly, beating more than 2.5 billion times during an average lifetime.  Diseases 
associated with this marvelous organ, however, remain the leading cause of death in the United 
States and are increasingly plaguing other developed and developing nations. The latest data 
suggest that 1 in every 4 deaths in the United States is attributable to heart disease and 
cardiovascular deaths represented 30% of all global deaths in 2008.2, 3 More than half of these 
are due to coronary heart disease. Significant medical advances have been made in both 
interventional techniques and pharmacological treatments used to prevent major injuries to the 
heart and fatalities, but many questions remain regarding the progression of cardiac remodeling 
after injury. Heart failure, or the inability of the heart to pump enough blood and oxygen to 
support other organs in the body, affects 5.1 million people in the US and costs the nation an 
estimated $32 billion each year in the cost of health care services and lost productivity.4 
Treatment options, especially those that have been shown to prolong life rather than simply 
provide temporary symptom relief, remain limited.  
In addition to treating the underlying pathology that led the heart to fail, heart failure is 
predominantly managed pharmacologically through the use of beta-blockers, angiotensin II 
receptors blockers, angiotensin converting enzyme inhibitors, diuretics, and in some cases, 
blood vessel dilators, aldosterone receptor antagonists, and digoxin. Inotropic therapy 
a Part of this chapter, particular the information on summary of purinergic receptors have been published 
previously: Yang R, Liang BT. “Cardiac P2X4 Receptors: Targets in Ischemia and Heart Failure?” Circ Res. 111:397-
401. 08/2012.  
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 (dobutamine, milrinone) may be used in end-stage disease to make the heart pump harder, 
forcing the heart muscle to contract more forcefully, and often also speeding up the heart’s 
rhythm. These therapeutics can relieve and control symptoms, but the risk of death rises if they 
are taken long term. Mechanical support in the form of a left ventricular assist device and 
ultimately heart transplant are last resort options.  
Many of the aforementioned pharmacological compounds have been developed based 
on structural and functional insights from biologically active molecules that regulate heart 
function.  Extracellular application of adenosine triphosphate (ATP) and its derivatives has been 
recognized to modify heart function for some time, with the first paper describing the effects of 
adenosine monophosphate (AMP) and adenosine published in 1929.5 Since then, molecular 
cloning has been used to identify a number of cellular receptors that respond to these 
extracellular nucleotides, which are collectively referred to as purinergic receptors, and there 
has been a rapid expansion of the purinergic field. Within the purinergic receptor family, the 
ligand gated P2X4 non-selective cation channel was previously identified as an important 
mediator of ATP’s effects in the endogenous murine heart. More interestingly, when mice with 
cardiac specific overexpression of this receptor were subjected to different models of heart 
injury/failure, they had better survival and preserved heart function. With this result in mind, in 
this thesis, we undertake a number of studies to derive mechanistic insight into how activation of 
this purinergic receptor impacts cardiomyocyte electrophysiology and contraction and how its 
downstream signaling affects heart function. We begin with a review of the electrical activities of 
the heart and excitation contraction coupling that serve as the basis of cardiac function and for 
understanding how purinergic ion channels can impact heart function.    
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 1.1 The cardiac action potential and its conduction 
In order to maintain rhythmic contractions throughout one’s life, the heart relies on an 
elegant electromechanically coupled system. Action potentials (APs), which coordinate 
contractions from muscles that pump blood to the rest of the body, are generated by defined ion 
fluxes through specific channels on the cardiomyocyte sarcolemma. The sinoatrial (SA) node 
residing in the right atrium of the heart is typically the dominant pacemaker, containing 
pacemaking cells capable of rhythmic spontaneous depolarizations. Their APs are distinct in 
that they contain an ionic flux known as the pacemaker current, or the “funny current” (If) (also 
described as Na+ (f), Figure 1.1A). If passes through a channel distinct from the fast sodium 
channel responsible for rapid depolarization in ventricular muscle cells. Rather, the pacemaker 
channel is activated by hyperpolarization and is thus open during repolarization of the cell, as 
the membrane potential approaches its most negative values. The inward flow of Na+ ions 
through the pacemaker channel then causes the membrane potential to become progressively 
less negative during repolarization and eventually, depolarizes the cell to its threshold voltage. 
The fast depolarization phase of the pacemaker cell AP is thought to rely mainly on Ca2+ influx, 
as the persistently less negative membrane voltage of pacemakers keep the fast sodium 
channels in these cells mainly inactivated.  Repolarization relies on inactivation of the calcium 
channels and increased activation of potassium channels leading to K+ efflux from cells (Figure 
1.1A).  
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During depolarization, the electrical impulse spreads rapidly between cardiac myocytes 
due to the presence of low-resistance connections known as gap junctions between neighboring 
cells. First, atrial muscle fibers propagate the impulse from the SA node to the atrioventricular 
(AV) node. Fibrous tissue surrounding the tricuspid and mitral valves ensures that there is no 
direct electrical connection between the atrial and ventricular chambers other than through the 
AV node.  The speed of tissue depolarization and the conduction velocity along cells depend on 
a number of factors, including the number of sodium channels, the magnitude of the resting 
potential, and fiber arrangement. Specialized regions, such as Purkinje fibers, can contain more 
densely arranged fiber and/or tissues with a high concentration of Na+ channels, which allow 
electrical impulse to spread quickly within and between cells for rapid conduction. After 
Figure 1.1 Cardiac Action Potentials 
Action potentials from the SA node (A) and ventricular myocytes (B) with corresponding ion 
permeabilities. The funny current If, or Na+ (f), gradually depolarizes SA pacemakers to 
reach threshold for opening of Ca2+ channels that are responsible for the AP upshoot. In 
ventricular myocytes, the membrane potential is stable until the depolarizing stimulus 
arrives, which leads to opening of fast Na+ channels responsible for the rapid depolarization. 
Repolarization is a balance of Ca2+ and K+ permeabilities. (Reproduced with permission 
from http://www.nataliescasebook.com/tag/cardiac-action-potentials)  
 
A B 
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 traversing the AV node, the cardiac AP spreads into the rapidly conducting bundle of His and 
Purkinje fibers, which then distribute the electrical impulses to the bulk of the ventricular muscle 
cells. A visual summary is provided in Figure 1.2, which also demonstrates more detailed 
differences in AP among different regions of the heart.   
 
 
Figure 1.2 The Cardiac Conduction Pathway 
The action potential is regularly initiated from the sinus node and propagated throughout the 
heart via specialized tracks and by cell to cell communication. The typical sequence of action 
potential travel and morphologies of different cell types found in each of the specialized regions 
of the heart are shown. The summation of these electrical signals gives rise to the 
electrocardiogram, which provides information about AP propagation. (Figure 6.7 from 
Malmivuo J and Plonsey R. “Bioelectromagnetism: Principles and Applications of Bioelectric and 
Biomagnetic Fields”. Reproduced with permission from Oxford University Press.) 
 
 
The AP of the ventricular muscle cardiomyocytes is morphologically and ionically 
different than that of the pacemaker cells (Figure 1.1B). The resting potential is typically more 
negative than the pacemaker resting potential. When a depolarizing influence is encountered, 
some sodium channels can open and the entry of Na+ ions into cells causes the transmembrane 
potential to become progressively less negative. When the threshold potential is reached, 
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 enough of these fast Na+ channels have opened to generate a self-sustaining inward Na+ 
current, resulting in a prominent influx of Na+ responsible for the rapid upstroke of the AP. The 
fast sodium channels then undergo rapid inactivation while transiently activated potassium 
channels are quickly activated by the large depolarization, which returns the membrane 
potential towards negative values. The plateau phase of the muscle AP is mediated by the 
balance of an outward K+ current in competition with an inward Ca2+ current though the L-type 
calcium channels.  These channels have a slower activation profile and remain open much 
longer compared with fast sodium channels. Calcium ions that enter the cell during this plateau 
phase are crucial in triggering additional internal calcium release from the sarcoplasmic 
reticulum for initiating myocyte contraction. Repolarization of the AP occurs with continued 
outward flow of K+ while Ca2+ channels gradually inactivate.   
 
1.2 Sarcolemmal ion channels and currents in the cardiomyocyte 
As previously mentioned, Na+ and Ca2+ influx are responsible for membrane 
depolarization and a number of K+ channels are responsible for repolarization. The voltage 
gated Na+ and K+ channels all consist of a primary α- and multiple secondary β-subunits. The α-
subunit is responsible for passing current while the β-subunits modify channel expression levels 
and regulate gating and channel kinetics. In contrast, the calcium channel is a combination of as 
many as 5 subunits, α1, α2, β, γ, and δ. A list of these currents, with their respective proteins for 
the primary α-subunits along with the encoding genes is included in Table 1.1. In addition to 
these voltage sensitive channel currents, a number of transporters act to return Na+ and Ca2+ 
ions that enter the cell during depolarization to the extracellular environment and to bring K+ 
back into the cell. Ca2+ ions are removed by the Na+-Ca2+ exchanger (NCX) and to a lesser 
extent by the plasma membrane Ca2+ ATPase pump (PMCA), while the Na+/K+-ATPase pump 
makes the corrective exchange of Na+ and K+. All three of these transporters are electrogenic, 
capable of generating currents that influence the AP and resting potential. 
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 Current Description Activation 
mechanism 
Clone Gene 
α-subunit of inward current channels 
INa Sodium current Voltage, 
depolarization 
Nav1.5 SCN5A 
ICa,L Calcium current,  
L-type 
Voltage, 
depolarization 
Cav1.2 CACNA1C 
ICa,T Calcium current,  
T-type 
Voltage, 
depolarization 
Cav3.1/ 
Cav3.2 
CACNA1G 
α-subunit of outward (K+) current channels 
Ito,f Transient 
outward current, 
fast 
Voltage, 
depolarization 
KV4.2/4.3 KCNF2/3 
Ito,s Transient 
outward current, 
slow 
Voltage, 
depolarization 
KV1.4/1.7/3.
4 
KCNA4/7, KCNC4 
IKur Delayed rectifier, 
ultrarapid 
Voltage, 
depolarization 
KV1.5/3.1 KCNA5/KCNC1 
IKr Delayed rectifier, 
fast 
Voltage, 
depolarization 
HERG KCNH2 
IKs Delayed rectifier, 
slow 
Voltage, 
depolarization 
KVLQT1 KCNQ1 
IK1 Inward rectifier Voltage, 
depolarization 
Kir 2.1/2.2 KCNJ2/12 
Specialized Outward Current  
If Pacemaker 
current 
Voltage, 
hyperpolarization 
HCN2/4 HCN2/4 
 
Table 1.1 Membrane Currents that underlie the Action Potential 
Modified with permission from Grant AO, “Cardiac Ion Channels”. Circulation: Arrhythmia and 
Electrophysiology 2009.6  
 
1.3 From Excitation to Contraction 
In response to APs generated by sarcolemmal ionic currents, cardiomyocytes contract 
by cycling calcium between the sarcoplasmic reticulum (SR) and the cytoplasm. Activation of L-
type Ca2+ channels results in a small influx of Ca2+ ions into the cell that is insufficient to cause 
contraction, but triggers a greater Ca2+ release from the SR, known as Ca2+ induced Ca2+ 
release (CICR). The T-tubule invaginations of the sarcolemmal membrane bring the L-type 
channels into close apposition with ryanodine receptors (RyRs) on the SR, which undergo a 
conformational change in response to the L-type channel Ca2+ influx to allow a much greater 
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 release of Ca2+ from the SR. A single L-type calcium channel can trigger SR Ca2+ release only 
from a locally apposed cluster of RyRs, and statistical recruitment of release clusters brings 
about graded release,7 in which the Ca2+  released from the SR is graded according to the 
amount of trigger Ca2+ entering the cell via L-type Ca2+ channels.8  
The sensitivity of troponin C to Ca2+ is the crucial link from Ca2+ transients to mechanical 
activity. Troponin is composed of three subunits; in addition to troponin C that binds Ca2+, 
troponin T links the troponin complex to actin and tropomyosin molecules, and troponin I inhibits 
the ATPase activity of the actin-myosin interaction that leads to crossbridge formation.  Actin 
and myosin are the chief force generating molecules in contraction. Myosin molecules are 
arranged in thick filaments, which are tethered by titin to the z-lines of sarcomeres. Actin is 
arranged in thin filaments as an α-helix of two strands that interdigitate between the thick 
myosin filaments. Under resting conditions, tropomyosin lies in the grooves between the actin 
filaments and inhibits the interaction between myosin heads and actin, preventing contraction. 
Ca2+ binding to tryponin leads to conformational change in tropomyosin, exposing active sites 
between actin and myosin filaments, allowing crossbridge formation and for the filaments to 
slide across each other.  As long as the cytosolic Ca2+ concentration remains sufficiently high to 
inhibit the troponin-tropomyosin blocking action of crossbridge formation between actin and 
myosin, progressive ATP-dependent reactions between the myosin head and actin causes the 
muscle fiber to shorten by increasing the overlap between the myofilaments within each 
sarcomere. Relaxation occurs when Ca2+ is removed from the cytosolic space, largely through 
sequestration back into the SR by the sarcoendoplasmic reticulum Ca2+ ATPase (SERCA) 
pump, while a smaller fraction is extruded into the extracellular space by the NCX and the 
PMCA.   
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 1.4 Computational Models of Cardiac Electrophysiology and Contraction 
The generation of the AP followed by excitation-contraction coupling is a highly dynamic 
process with a carefully timed sequence of events that occur on the millisecond scale. To 
understand these complex interactions, quantitative modeling has been utilized to analyze each 
process, and is exemplified by the original Hodgkin-Huxley description of the squid giant axon 
AP, which has been the standard for describing voltage-dependent membrane ion current 
dynamics for over 60 years.9 This model introduced the concept of channel gating, and related 
currents through ensembles of channels to the state of these gates. The first computational 
model of a cardiac myocyte, the Purkinje cell, was developed based on the Hodgkin-Huxley 
formalism and was presented by Denis Noble in the early 1960s.10 Early models explored 
mechanisms underlying the long AP duration observed in cardiac myocytes compared to 
neurons, which was explained as a balance between a maintained inward Na+ current and a 
slowly activating outward K+ current. Relative Na+ and K+ conductances could be adjusted to 
produce a stable resting potential or a stable oscillation that mimicked the oscillatory long 
duration APs of the cardiac Purkinje fiber. While we now know that the inward current during the 
plateau phase of the cardiac AP is primarily due to membrane Ca2+ permeability and that the 
conclusions of the earliest models were inaccurate, they were nonetheless fundamentally 
important in trying to achieve detailed mechanistic and quantitative understanding of the 
cardiomyocyte AP. Subsequent elaborations led to the development of the 1985 DiFrancesco-
Noble model 11, which has become a template for pacemaking cell models. In addition to 
including hyperpolarization activated If conductance for pacemaking in the Purkinje fiber, it also 
incorporated time-varying concentration of ions in the cell, activities of the Na+/K+ ATPase and 
NCX, and voltage and calcium dependent inactivation of the calcium current.  It also introduced 
components of subcellular Ca2+ movement, where Ca2+ is taken into the SR by SERCA and can 
diffuse from the nonjunctional SR (NSR) to the junctional SR (JSR) for CICR from the JSR. All 
subsequent models of the cardiomyocyte have been built based on this framework.  
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 The first ventricular cell model based on voltage clamp recordings obtained from isolated 
myocytes was reported in 1991.12 This first Luo and Rudy model based on data from guinea pig 
ventricular myocytes described six distinct membrane currents and substantially progressed the 
field, as current descriptions were carefully based on existing experimental data and model 
equations were fully published to enable implementation by other investigators. Their second 
model published in 1994 included sarcolemmal pumps and exchangers, intracellular Ca2+ 
buffers, CICR and Ca2+ cycling. The development of quantitative models greatly benefited from 
technical advances in the spatiotemporal control of single cell voltage clamping, which allowed 
for increasingly sophisticated experiments to generate more detailed data and even leading to 
single channel measurements. Concurrent with these new technical advances, subsequent 
models have become increasingly biophysically detailed. Markov chain models are now 
commonly used to describe gating behavior, and are comprised of a number of different states 
that loosely correspond to different conformations of channel proteins as they undergo 
activation and inactivation, with transition rates between certain states being voltage-dependent. 
The Markov property of “memorylessness” assures that the future evolution of the process state 
depends only on the current state and overcomes the limiting assumption of Hodgkin-Huxley 
that channel gates behave independently. More detailed descriptions of CICR mechanisms 
represent another area of advance in the modern model of the cardiac myocyte. Statistical 
recruitment of calcium release units underlying graded calcium release can be modeled by 
including a population of dyadic Ca2+ release units in which local interactions of individual 
sarcolemmal L-type calcium channels and nearby RyR are simulated stochastically13. As the 
computational resources involved in such modeling can be overwhelming, simplified local 
control models of CICR are often formulated by applying a carefully chosen set of 
approximations that allow for the ensemble behavior of Ca2+ release units to be represented by 
simple ordinary differential equations14. These important modeling features are included in the 
Bondarenko model15 (Figure 1.3), which was parameterized to fit experimental observations  
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Figure 1.3 Excitation-Contraction Coupling as presented in an Integrated 
Cardiomyocyte Model 
(A) Major membrane ionic currents that give rise to the AP are shown, with L-type calcium 
channel current ICaL coupled to calcium release from the junctional SR. Rising cytosolic Ca2+ 
can bind to tryponin, leading to myofilament overlap that generates contraction. Depolarizing 
currents INa and ICaL, repolarizing K+ currents IKto,f, IKto,s, IKs, IKr, IKur, IKss, IK1, transporter and 
pump currents INaK, INaCa, Ip(Ca), background currents INab, ICab, and a calcium activated chloride 
current ICl,Ca were included in this model of the murine ventricular myocyte.  Markov 
descriptions of gating mechanisms were implemented for INa, ICa,L, and IKur. (B) Sequence of 
AP initiation to force generation for a representative cardiac beat. (C) Dynamics of underlying 
currents for a typical AP. Top panel illustrates a typical mouse AP as outputted by the 
computational model. Middle panel demonstrates the large currents shaping the AP, note the 
axis for INa is on the right. By convention, inward positive ion movement constitutes a negative 
current. Notice the rapid time course for INa and the balance between ICa,L and outward going 
K+ currents during the repolarization phase. Bottom panel shows smaller magnitude ion 
movements that are active both during AP firing and at rest. (Figures reproduced with 
permission from Bondarenko et al, 2004 and Mullins et al, 2013.15, 16 )      
A C  
 
 B 
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 from murine myocytes. Since our experiments are based in mice, which are amendable to 
genetic modification and experimental manipulation, this mouse ventricular myocyte model 
serves as the basis of further computational modifications and study in this thesis as well. 
 
1.4.1  Comparison of the Mouse vs. Human action potential 
While the fundamental mechanism of excitation contraction coupling is similar in the 
mouse compared to the human heart, a number of differences are worth noting. In the mouse 
heart, the L-type Ca2+ current contributes less to the ventricular AP than in humans, and 
therefore the murine AP shows a gradual repolarization rather than a distinct plateau phase. In 
humans, the plateau phase ends when the balance shifts from the slowly inactivating ICa,L to 
slowly activating potassium currents, giving rise to the final repolarization until the resting 
potential  is restored. In human ventricular myocytes, Ito,f  is mainly involved in the first phase of 
repolarization and IKr and IKs are predominantly responsible for the late repolarization, whereas 
the much faster repolarization in murine ventricles is mediated by Ito,f, Ito,s, IKs, and a non-
inactivating steady state K+ current (IKss). The equivalent of the murine IKss has not been 
detected in human ventricles.17 Ca2+ handling is somewhat different in mice, where up to 90% of 
Ca2+ is taken back up into the SR.18, 19 In larger mammals, approximately 70% of Ca2+ is taken 
back into the SR and 30% is eliminated by the NCX and PMCA. Murine myocytes also have a 
higher cytoplasmic Na+ concentration than larger mammals, which favors less extrusion of Ca2+ 
by the NCX, consistent with a higher fraction of  SR Ca2+ reuptake.20 While an increase in heart 
rate often leads to enhanced SR Ca2+ loading by decreasing the diastolic period for calcium 
extrusion, leading to greater contractile force at higher heart rates in larger mammals, the lower 
fraction of NCX-mediated Ca2+ extrusion in mice could explain why an increase in heart rate 
hardly affects SR Ca2+ load in mice. Combined with refractoriness of excitation contraction 
coupling, in which reduced fractional SR calcium release occurs at higher frequencies, a 
negative force-frequency relationship prevails in the mouse.20 While important differences exist 
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 between the mouse and larger mammals, transgenic mouse models are still a valuable tool for 
preclinical studies and results should be interpreted with these differences in mind. 
 
1.5 Overview of Purinergic Receptors 
Purinergic receptors were initially conceived to describe the likely existence of 
membrane receptors responding to ATP (P2 receptors) or its breakdown product adenosine (P1 
receptors) in causing non-adrenergic, non-cholinergic relaxation of gut smooth muscle.21 
Cloning of these receptors has yielded insights into their properties and signaling mechanisms, 
allowing further P2 classification into sub-families of seven ionotropic (P2X) and eight 
metabotropic (P2Y) receptors based on structure.22 P2X channels respond to ATP as their only 
endogenous ligand and are organized as homo- or hetero-trimers of two transmembrane 
domain subunits that form non-selective cation channels, though some channels have been 
demonstrated to allow passage of anions and large molecules.23 The P2Y receptors are G-
protein coupled receptors that have recently been shown to form hetero-oligomers as well.24 In 
addition to endogenous ATP and ADP, P2Y receptors respond to the pyrimidines UTP and UDP. 
P2Y1, P2Y2, P2Y4, and P2Y6 are coupled to Gq to activate PLCβ, leading to IP3-mediated 
mobilization of intracellular calcium storage, while P2Y12, P2Y13, and P2Y14 couple to Gi and 
thus inhibit adenylyl cyclase. P2Y11 uniquely couples to both Gq and Gs to increase calcium and 
cAMP (summarized in Figure 1.4).  
Purinergic receptors are now associated with a number of important roles in normal and 
patho-physiology25. Adenosine has been employed extensively as a vasodilator and an anti-
arrhythmic, and efforts to target each adenosine receptor subtype as novel therapies are 
ongoing.26 P2Y12 antagonists are also utilized as cardiovascular therapies27 and 
pharmacological interest exists for a number of other P2 receptors for a wide range of clinical 
applications,28, 29 with the P2X class most notably targeted for chronic pain treatment and 
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 immunomodulation.30 Here we focus our attention on P2 receptors in the heart, and more 
specifically on novel aspects of the P2X4 receptor. 
 
1.6 P2 receptors in the heart 
Studies of ATP’s effects on the heart predate the conception of purinergic receptors. 
While extracellular ATP concentration is typically in the nanomolar range, ischemic events can 
cause an increase up to hundreds of micromolars,31 leading to the activation of the myriad of 
receptors described in Figure 1.4. Some of the earliest studies of extracellular ATP application 
were motivated by its large increase in injury/trauma,32, 33 though it wasn’t realized until later that 
Figure 1.4 Summary of Purinergic Signaling.  
Three broad categories of receptors respond to extracellular purines and pyrimidines. P2X 
refers to nonselective cation channels that respond to ATP, with some subtypes 
demonstrating the ability to pass anions and large molecules. P2Y receptors are G-protein 
coupled receptors that respond to endogenous ATP and ADP, as well as the pyrimidines 
UTP and UDP. Activation of P2Y1, P2Y2, P2Y4, and P2Y6 lead to Gq coupled PLCβ 
signaling, leading to IP3-mediated mobilization of intracellular calcium storage. P2Y12, 
P2Y13, and P2Y14 couple to Gi and thus inhibit adenylyl cyclase. P2Y11 is uniquely coupled 
to both Gq and Gs and can increase calcium and cAMP. Further breakdown of ADP to 
AMP and adenosine can then lead to activation of adenosine receptors (also referred to 
as P1 receptors or A receptors), which are also G-protein couple receptors. Three 
subtypes have been identified, with A1 and A3 stimulating Gs while A2 is coupled to Gi.  
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 the cardiac muscle cells can also release ATP in response to hypoxia.34 Many of the early 
identified effects on the heart have been shown to be mediated by adenosine due to the fast  
breakdown of ATP to adenosine by extracellular ectonucleotidases.35 Adenosine is thought to 
be the main active compound responsible for the negative chronotropic, heart block, and 
vasodilatory effects seen with ATP administration, which is the basis for utilizing ATP bolus 
injections as an anti-arrhythmic to terminate supraventricular tachycardia.36, 37 Additionally, 
adenine nucleotides given to isolated perfused mammalian hearts often caused a positive 
inotropic effect, in many cases shown to be exerted directly on the myocardium rather than 
through the vasodilatory effects of these compounds.38 Increasing the phosphorylation status of 
adenosine (ATP> ADP> AMP) correlated well with an increasing effect on cardiac contractility, 
whereas adenosine itself had no direct effect on cardiac contractility,38 suggesting P2 receptor  
mediated contractile enhancement. This effect has also been described in the human 
myocardium.39 However, as the rate of degradation of these compounds in vivo is difficult to 
control and the large number of possible receptors lead to combinatorial complexity that is 
difficult to unravel, the effects of ATP on the heart and the mechanisms leading to them are still 
 
Reference Species Cardiac 
region 
Disease Receptors present 
Banfi C, et 
al. 2005 
Human LV CHF & 
healthy 
All at the mRNA level.  
Protein not confirmed for P2X5 & P2Y2 
P2X6 upregulated in CHF 
Musa H, et 
al. 2009 
Human RA and 
SAN 
Healthy mRNA for P2X4-7 and P2Y1,2,4,6,12-14 
P2X: P2X4, 7 most abundant 
P2Y: P2Y1, 2 most abundant in RA,  
         P2Y1, 2, 14 most abundant in SAN 
Rat LV, RA, 
and 
SAN 
Healthy 
vs. 
Coronary 
artery 
ligation 
Healthy 
P2X: P2X5 most abundant in all regions 
P2Y: P2Y1, 12, 14 most abundant in LV 
          P2Y2,13 highest in RA & SAN 
Coronary artery ligation 
P2X4 mRNA upregulated by 93% in the 
SAN, non-significant increase trend in the 
RA & LV 
Table 1.2 Widespread P2 receptor expression in cardiac tissue.  
Note regional and species differences. CHF= Congestive heart failure, LV = left ventricle, RA = 
right atrium, SAN = sinoatrial node.  
15 
 
 debated. It is worth noting that transcripts for all P2 subtypes have been detected in the hearts 
of human and rodent,40, 41 and additional changes and regulations can occur during 
pathological conditions (Table 1.2). Overall, a better understanding of the role of cardiac P2 
receptors and their regulation in diseased hearts is likely to have implications for preventing 
and slowing the progression of disease.   
In isolated cardiac cells, early experiments in adult rat myocytes showed that 
extracellular ATP evoked a transient increase in intracellular Ca2+ concentration in quiescent 
cells, and that extracellular Ca2+ influx was necessary for this change.42-45 ATP stimulated the 
trans-sarcolemmal influx of Ca2+, whereas ADP, AMP and adenosine were ineffective.38, 45. This 
was associated with an ATP-activated inward current that had a reversal potential near 0mV, 
suggesting the presence of ATP-gated cation channels in the cardiomyocyte, and was further 
accompanied by depolarization towards the threshold of AP firing in rat myocytes.45 Under 
quiescent conditions, oscillatory contractions could be induced, in which the frequency but not 
the amplitude was regulated by the concentration of extracellular ATP.46 Ca2+ release and 
uptake by the SR was necessary for the observed oscillations in intracellular Ca2+ concentration 
and contraction. During electrical stimulation, extracellular ATP activation of purinergic receptors 
was shown to both potentiate the amplitude of electrically stimulated contractions and induce 
spontaneous contractions.42, 46  
The extracellular ATP induced inward current has been replicated in various species.44, 47, 
48 In adult ventricular myocytes from healthy wild type mice, P2 agonism caused an increase in 
a non-selective cation current.49 An analogue of ATP with a methylthio group in place of 
hydrogen in position 2 of the adenine nucleobase: 2-methylthioadenosine-5'-o-triphosphate (2-
meSATP), was used for its higher resistance to nucleotidase breakdown and its inability to 
activate P2Y receptors (thought at that time) and coronary vasodilatory (adenosine) effects 50 to 
limit the impact of confounding factors on the heart. The reversal potential of this current was 
similar to that of the cloned P2X4 receptor.47  Furthermore, the current induced by 2-meSATP 
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 was partially insensitive to antagonism by suramin and pyridoxalphosphate-6-azophenyl-2′,4′-
disulphonic acid (PPADS), which is also a characteristic of the P2X4 receptor.47, 49 The P2X4 
receptor, structurally similar to others in the P2X family, have EC50 for ATP similar to P2X2,5,6, 
higher than P2X1,3, and approximately one order of magnitude lower than P2X7. Its unique 
property of being potentiated by ivermectin also allows for its identification.  
 
1.7 Cardiac specific manipulation of the P2X4 gene in mice 
A reductionist approach led to identification of the P2X4 channel as a likely important 
endogenous component of the cardiac response to P2 agonism. To further understand the 
effects of this channel, a cardiac specific overexpression mouse model was created by 
subcloning the human P2X4 cDNA into an expression vector carrying the alpha myosin heavy 
chain (α-MHC) promoter, which confers cardiac specific expression.51 After sequence 
verification, the recombinant clone was purified and microinjected into the male pronucleus of 
the B6SJL/F1 mouse zygote, which was then implanted in pseudopregnant female mice. 
Founders and subsequent generations of transgenic mice were identified by PCR and 
immunoblotting for protein expression. Immunoblotting suggested an average of 20 fold 
overexpression over wildtype while electrophysiological data demonstrated an approximate 
doubling of inward current with 3µM of 2-meSATP treatment.47  
2-meSATP induced a greater increase of contractility in cardiac myocytes isolated from 
these transgenic mice than in wild type myocytes,51 further indicating that the P2X4 receptor has 
a physiological effect in native murine myocytes and that the signal can be augmented with 
transgenic overexpression. Under basal control conditions, these mice with cardiac specific 
P2X4 receptor overexpression (P2X4ROE) were overtly normal without cardiac hypertrophy or 
failure as they age.51 Their response to cardiac injury, however, proved more interesting. These 
mice were shown to be protected from a genetic model of calsequestrin (CSQ) overexpression-
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 induced heart failure (HF),52, 53 in which CSQ binds to Ca2+ in the SR and impairs its release 
during cardiac cycles. The expression of the cardiac P2X4 receptor was increased in the CSQ 
overexpressing model of hypertrophy and dilated cardiomyopathy, and the 2-meSATP-
stimulated current was also greater in ventricular myocytes isolated from the CSQ mice as 
compared to WT mice. This indicated a possible role for the P2X4 receptor in pathophysiology 
but also suggested a potentially compensatory mechanism, as P2X4R OE/CSQ OE double 
transgenic mice had improved survival and cardiac function.52  Moreover, in the more disease 
relevant model of left anterior descending coronary artery ligation to induce ischemia and 
consequent HF, the P2X4R OE mice showed improved survival and better preserved cardiac 
function as compared to WT (Figure 1.5 and Table 1.3).1 P2X4R expression, as assessed by 
immunoblotting for protein, did not change in the remote non-infarcted region in post-infarct WT 
mouse hearts, though it has been shown to be up-regulated in the right ventricles of rats 
exposed to hypobaric hypoxia.54 The downstream mechanism(s) by which this ATP-gated non-
selective cation channel protects against myocardial functional deterioration is still incompletely 
understood, but the inotropic support offered by P2X activation may supply the needed 
functional enhancement during the critical period after ischemic injury.1 
 
Figure 1.5 Improved Survival in P2X4R overexpression mice after ischemia injury 
P2X4 receptor overexpression transgenic (P2X4R Tg) mice demonstrated less mortality 
after myocardial infarction (MI) induced by left anterior descending coronary artery ligation 
in both (A) females and (B) males. Gender differences are consistent with known improved 
outcome in females. (Figure reproduced with permission from Sonin, et al. 2008.1)   
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Table 1.3 Echocardiographic parameters in WT and P2X4ROE animals after Ischemic Injury 
Females 
Time After MI N FS, % LVPW Thickening, mm LVEDD, mm LVESD, mm MI Size, % 
7 days       
WT 28 20.50±0.59† 0.059±0.0047† 3.87±0.0840† 3.08±0.0770† 40.4±4.02† 
P2X4R OE 
1 month 
21 22.60±0.84* 0.079±0.0100* 3.91±0.0970† 3.05±0.0850† 38.3±3.37 
WT 19 18.80±0.59 0.053±0.0055 3.91±0.1100 3.18±0.0950 43.2±2.90 
P2X4R OE 
2 months 
14 24.20±0.77* 0.080±0.0100* 4.19±0.1350 3.19±0.1220 40.5±3.14 
WT 22 18.49±0.56 0.040±0.0052 4.27±0.1600 3.51±0.1430 27.0±2.03 
P2X4R OE 17 23.14±0.76* 0.102±0.0140* 4.39±0.1590 3.39±0.1370 30.5±3.20 
 
 Males 
Time After MI N FS, % LVPW Thickening, mm LVEDD, mm LVESD, mm MI Size, % 
7 days       
WT 28 17.65±0.49 0.051±0.0047 4.34±0.0870 3.53±0.10 44.8±3.67† 
P2X4R Tg 
1 month 
21 24.50±0.95*† 0.090±0.0083* 3.98±0.1600* 3.14±0.13* 38.1±4.22 
WT 14 18.23±0.85 0.035±0.0056 4.33±0.1500 3.57±0.14 44.0±1.92 
P2X4R Tg 
2 months 
10 22.72±1.14* 0.090±0.0160* 4.57±0.2190 3.55±0.21 42.3±1.83 
WT 23 17.15±0.88 0.053±0.0055 4.29±0.1600 3.53±0.15 31.9±1.73 
P2X4R Tg 18 20.42±0.98* 0.087±0.0096* 4.62±0.2900 3.68±0.26 33.6±4.90 
Values are means ± SE. At 7 days, 1 month, and 2 months after LAD ligation-induced myocardial infarction, WT and P2X4R OE 
mice of either sex were subjected to echocardiography evaluation of cardiac function. The various echocardiographic measurements 
were obtained as shown. FS=fractional shortening, LVPW=left ventricular posterior wall, LVEDD=left ventricular end diastolic 
dimension, LVESD=left ventricular end systolic dimension. MI size was determined by histology with Masson Trichrome 
staining. *P < 0.05 vs. WT mice at the same time point after MI. †P < 0.05 vs. the 2-month time point. (Table reproduced with 
permission from Sonin, et al. 2008.1)  
 
 
 Further characterization of the effects of 2-mesATP in P2X4ROE cardiac myocytes 
showed that the enhanced myocyte contractile response was not accompanied by any 
change in the L-type calcium channel current-voltage relationship. This observation, along 
with the lack of depolarization in response to 2-meSATP (re-examined in Chapter 3), 
indicated no Ca2+ influx via the L-type Ca2+  channel during P2X agonism.55 However, 
increased SR calcium loading was seen in P2X4R OE transgenic myocytes with exposure to 
agonist, providing a mechanism for P2X4 receptor-mediated increase in contractility and 
suggesting that another source of Ca2+ may be involved. Among the P2X receptors, P2X4 is 
one of the most Ca2+ permeable, though the majority of entering ions are still Na+. Enhanced 
Na+ entry via overexpressed P2X4 channel may act to further increase Ca2+ by affecting the 
NCX, which we further explore in the next chapter. Localized domains of Ca2+ increase at 
the plasma membrane may activate Ca2+-dependent protein(s) in close vicinity of the 
receptor channel, after which diffusion of Ca2+ may reach the SR to enhance its loading.  
Endothelial nitric oxide synthase (eNOS) is one possible interacting protein activated 
by Ca2+ and calmodulin. Studies on a global P2X4R knockout mouse model have 
demonstrated that this receptor is an important mechano-transducer in endothelial cells, with 
P2X4R knockout endothelial cells exhibiting abnormal shear responses. This was 
demonstrated to be due to a lack of force-induced Ca2+ influx and subsequent nitric oxide 
production.56 This role in maintaining flow-induced vasodilation is important in physiological 
vascular homeostasis, as a single nucleotide polymorphism leading to decreased ATP 
binding was recently associated with increased pulse pressure in humans.57 No cardiac 
performance observation has been mentioned about the P2X4R knockouts, presumably due 
to a lack of significant basal phenotype change, though it would be of interest to see if 
exposing these animals to cardiac insult exposes a diseased phenotype. Given a possible 
link between P2X4 receptors and eNOS, as well as the known cardioprotective effect of nitric 
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 oxide and cGMP-dependent protein kinase (PKG),58 it is intriguing to suspect a role for 
eNOS in mediating an anti-hypertrophic effect, offering protection from ischemia injury and 
development of heart failure in the P2X4R OE mice (Chapter 4). 
 
1.8 Aims and Significance of this Research 
By combining experiments with computational modeling, we sought to understand 
the effect of the P2X4 channels on cardiac function in the integrated framework of excitation 
contraction coupling.  In light of previous work on this channel, which demonstrated inotropic 
enhancement and protection in ischemic injury, a number of aims to assess the risks and 
feasibility of targeting these receptors in the treatment of cardiac disease were developed 
and the results are presented in the referred chapters.     
 
AIM 1: To understand P2X impact on cardiomyocyte Na+ handling and its possible 
involvement in contractile enhancement (Chapter 2) 
 We examine if Na+ influx via the P2X4 channel can modify activities of other important 
transporters in cardiac myocytes, namely the Na+/K+-ATPase pump and the NCX. Increased 
intracellular Na+ concentration can favor the Ca2+ entry mode of the NCX, whereby Na+ is 
pumped out in exchange for Ca2+ entry, thus enhancing the calcium transient and 
contraction. We quantify the level of intracellular Na+ concentration change in response to 
purinergic activation and test whether the NCX may be involved in P2X-elicited 
enhancement of contraction.  
 
AIM 2: To test cardiomocyte and whole heart excitability following P2 agonism 
(Chapter 3) 
 The flow of positive charge into the cell can induce depolarization, which in the 
context of a cardiomyocyte can alter AP generation and its propagation in the whole heart. 
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 ATP has been suggested in some studies to cause spontaneous electrical activities and 
arrhythmias, though the mechanism is not entirely understood. We take advantage of our 
P2X4R overexpressing hearts to test whether cellular excitability and whole heart ectopic 
activity is increased with activation of these channels. 
 
AIM 3: To examine if nitric oxide signaling is activated following P2 agonism and 
whether it has a role in P2X4R-mediated protection (Chapter 4) 
  Nitric oxide signaling, particularly through eNOS, is one of the calcium dependent 
pathways known to be protective against injury and heart failure. P2X4 receptor dependent 
eNOS activation has been suggested in vascular endothelial cells. We test if there is an 
interaction between P2X4R and eNOS in the cardiomyocyte and if this mediates P2X4R 
overexpression conferred cardioprotection. 
  
The research presented here makes significant contributions to understanding how 
purinergic channels can affect heart function. Genetically modified animals allow us to 
further dissect mechanisms underlying ATP-mediated effects, which remain largely elusive 
due to challenges in pharmacology.  We build upon findings from the cardiac specific P2X4R 
overexpression mouse and utilize additional genetic and pharmacological tools to derive new 
insight into the mechanisms that could underlie P2X4R overexpression mediated protection. 
Furthermore, with the computational framework of the cardiomyocyte in mind, we consider 
the dynamics of the P2X current in re-evaluating prior controversies in the field on ATP-
induced arrhythmogenesis. Our results suggest that P2X receptors may be a viable target 
for cardiac treatment with transient effects on excitability.  
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 Chapter 2 
Cardiac P2X Purinergic Receptors as a New 
Pathway for Increasing Na+ Entry in Cardiac 
Myocytesb 
 
2. 1 INTRODUCTION 
Intracellular Na+ concentration and its homeostasis are important in regulating the 
contractile and electrical activity of the heart.59  The sarcolemmal Na+-K+ ATPase (Na+ pump) 
utilizes energy derived from the hydrolysis of ATP to generate an outward pump current 
carried by Na+ at rest as well as during action potentials to maintain resting potential.60 The 
Na+/Ca2+ exchanger (NCX) is a major mechanism of Ca2+ extrusion in the cardiomyocyte, but 
through its Ca2+ entry mode can also extrude Na+ from the cardiac myocytes.61, 62  P2X 
receptors are ligand-gated ion channels which are permeable to Na+, K+ and Ca2+ with a 
reversal potential near 0 mV.63, 64 Extracellular ATP, a P2X receptor ligand, can induce a 
nonselective cationic current in murine,47 rat,44 and guinea pig48 cardiac ventricular myocytes.  
Under normal extracellular Ca2+ concentration (1.8mM), Ca2+ contributes about 8% of the 
total inward current induced by ATP via homotrimeric human P2X4R expressed in HEK 
cells.65  However, most of the ATP-induced inward current is carried by Na+.47, 65  To confirm 
the functional importance of this Na+ entry pathway, we examined the effects of Na+ entry via 
P2X receptors on the activities of either Na+-K+ ATPase or NCX as each is sensitive to 
b This chapter is adapted from a prior publication: Shen JB*, Yang R*, Pappano A, Liang BT. “Cardiac 
P2X purinergic receptors as a new pathway for increasing Na+ entry in cardiac myocytes”. Am J 
Physiol Heart Circ Physiol. 2014 Nov 15; 307 (10):H1469-77. *First 2 authors contributed equally. 
 
J.B.S. and R.Y. performed experiments; J.B.S., R.Y., A.J.P., and B.T.L. analyzed data; R.Y. carried out 
mathematical simulations; J.B.S. and R.Y. prepared figures and drafted manuscript; J.B.S., R.Y., A.J.P., 
and B.T.L. approved final version of manuscript; R.Y., A.J.P., and B.T.L. interpreted results of 
experiments; A.J.P. and B.T.L. participated in conception and design of research; A.J.P. and B.T.L. 
edited and revised manuscript. 
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 intracellular Na+ changes. Myocyte contraction was also tested in the presence of Ca2+ entry 
mode NCX inhibitors, KB-R 7943 and YM-244769, to determine the role of the NCX in 2me-
SATP-stimulated contraction. Studies were carried out in P2X4R overexpression cardiac 
ventricular myocytes to facilitate detection of an effect on Na+-K+ ATPase and NCX activities 
by P2X agonist.  Current-voltage (I-V) relationships of the Na+ pump and NCX were also 
simulated with mathematical modeling. Similar studies were carried out in ventricular 
myocytes of wild type (WT) mice to explore the physiologic relevance of this receptor in 
modulating Na+ handling. 
 
2. 2 MATERIALS AND METHODS 
 
2.2.1 Isolation of Adult Cardiac Myocytes 
P2X4 receptor overexpression (P2X4R OE) mice were generated and bred as 
previously described.51, 55, 66 Animals were maintained according to protocols approved by 
the Institutional Animal Care and Use Committee at the University of Connecticut Health 
Center and conform to the Guide for the Care and Use of Laboratory Animals from the 
United States National Institutes of Health. Cardiac ventricular myocytes were obtained from 
3-month-old cardiac specific P2X4R OE or WT mice of either sex using an enzymatic 
dissociation procedure.47 Briefly, the heart was rapidly excised from mice that had been 
adequately anesthetized using a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg).  
Animals were also anti-coagulated with 1000 U of intra-peritoneal heparin. The aorta was 
cannulated while visualized under a surgical microscope, then we perfused the heart on a 
Langendorff apparatus at 37°C with a calcium-free oxygenated buffer containing (in mM): 
125 NaCl, 4.4 KCl, 1 MgCl2, 4 HEPES, 18 NaHCO3, 11 glucose, 3 2,3-butanedione 
monoxime, pH 7.3. After 2-3 min, the coronaries were free of blood, and the perfusion buffer 
was switched to the same buffer containing 0.08mg/mL Liberase Blendzyme 4 (Roche 
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 Molecular Biochemicals) and 25µM CaCl2 for 10 min. The left ventricles were minced and 
titurated to yield myocytes. Myocytes were then exposed ultimately to and kept at 1.0mM 
external CaCl2 for studies. Myocytes that maintained a rod shape without blebs or blurred 
striation in light microscopy were studied. For contraction studies, myocytes also needed to 
meet the criteria of remaining quiescent without spontaneous contraction at baseline while 
capable of generating contractions when electrically paced. The experiments were carried 
out at room temperature (22 to 23°C) and were completed within 5 h after myocyte isolation.  
 
2.2.2 Whole cell patch-clamp method 
The whole cell patch-clamp technique was used for the experiments. Electrodes 
were prepared from borosilicate glass pipette (1.2 mm i.d.) with a two-step pulling procedure 
and filled with pipette solution (see below). Electrode resistances were 2–4 MΩ. The pipette 
was connected via an Ag-AgCl wire to the head stage of an amplifier (List EPC-7, Medical 
Systems, Greenvale, NY). After electrical contact was established for a few minutes, 
membrane capacitance was calculated from a -5 mV voltage step. Voltage commands and 
data acquisition were accomplished with Axon pClamp software version 9.0. 
 
2.2.2.1 Na+/Ca2+ exchange current (INCX) measurement 
To measure INCX, electrodes were filled with a solution containing (mM): 135 cesium 
aspartate, 5 Na2ATP, 3 MgCl2, 10 HEPES, and 10 EGTA (pH 7.3 adjusted with CsOH). The 
outlet of the rapid solution changing device (SF-77B, Warner Instrument) was brought within 
50 µm of the cell. Then the superfusion medium was changed to a modified Tyrode’s 
solution (5.4 mM KCl was omitted and 10 mM CsCl, 10 µM nifedipine and  5 µM ouabain 
were added to Tyrode’s solution) to block K+ currents, L-type Ca2+ current (ICaL) and the Na+ 
pump current (Ip), respectively. The voltage protocol used to elicit INCX was as follows: from a 
holding potential of -80mV, a brief 10ms step to +80mV was followed by a 2 s repolarizing 
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 ramp to -100mV. The ramp was applied to myocytes three times at one second intervals and 
then the superfusing fluid was rapidly changed to a solution containing 10 mM NiCl2 for 10 s. 
At the end of the Ni2+ application, the same ramp protocol was applied again.  Three Ni2+-
sensitive current traces from 60 mV to -100 mV were averaged to construct the I-V 
relationship of INCX under control conditions.67, 68  Then, 3 µM 2-meSATP was added to the 
superfusion solution for 3-4 min while the myocyte was clamped at -80mV.  The same 
procedures of ramp protocol and rapid solution change were applied again in the presence 
of 2-meSATP. The I-V relationship of INCX, taken as the Ni2+-sensitive current, was compared 
in the absence and presence of 2-meSATP.  
To measure only the Ca2+ entry mode of INCX, the current at +30mV was continuously 
recorded before and after rapid application of 10mM Ni2+. During the subsequent 2-meSATP 
exposure, the myocyte was held at -80mV to promote Na+ entry. After 3-4 min, the holding 
potential was changed to +30mV again and the Ni2+ was applied to block the Ca2+ entry 
mode of INCX.  
 
2.2.2.2 Na+-K+ ATPase current (Ip) measurement 
Myocytes were voltage-clamped with the same pipette solution as in INCX experiments. 
Pipette Na+ was varied from 5-100 mM by equimolar adjustment of Cs+ and Na+ 
concentrations. After electrical contact was established and the membrane capacitance was 
obtained, the bath solution was then changed to a zero-K+ Tyrode’s solution to block Ip. The 
solution also contained 5mM NiCl2 to block INCX and ICaL.69, 70 The holding potential was set to 
-80mV to promote the 2-meSATP-induced inward current. Ip was measured as the K+-
activated outward current elicited by rapidly changing the extracellular solution from zero-K+ 
to 5.4 mM K+-modified Tyrode’s solution for 5 s. The holding potential was switched to -
20mV to obtain the maximal activation of Ip. Peak Ip was selected to evaluate Na+-K+ATPase 
activity before and after 2-meSATP application, since the Na+ changes sensed by Na+-K+ 
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 ATPase are more accurately reflected by peak Ip than the steady Ip.69 The brief exposure to 
extracellular solution minimized the change of intracellular ion environment during 2-
meSATP application. After the peak Ip was obtained at control, 3µM 2me-SATP was added 
to the superfusion solution for 3-4 min while the myocyte was clamped at -80mV and then 
the peak Ip was measured again. Peak Ip after 5 min washout was also obtained.  
 
2.2.3 Cell shortening measurement 
Cell shortening (CS) of ventricular myocytes was elicited by field stimulation at 0.5 Hz 
and was detected by a video edge-detector device (Crescent Electronics, Sandy, UT) as 
previously described.66  
 
2.2.4 Data and Statistics 
INCX and Ip (pA) were normalized to membrane capacitance (pF). All data are shown 
as mean± SEM. Student’s t test for paired samples was used for statistical analysis, unless 
otherwise indicated.  
 
2.2.5 Mathematical Simulation 
Simulated current I-V relationships for INCX and Ip are based on previous 
formulations.71 The equation for Ip is 𝐼𝑝 = 𝐼𝑝� × 𝑓𝑝 × 1
1+(𝐾𝑚,𝑁𝑎𝑖
�𝑁𝑎+�𝑖
)1.5 × [𝐾+]𝑜[𝐾+]𝑜+𝐾𝑚,𝐾𝑜, where the last 
two terms describe pump dependence on [Na+]i and [K+]o, and the 𝑓𝑝 term defines the 
dependence of the pump current on voltage: 𝑓𝑝 =  1
1+0.1245 × 𝑒−0.1𝑉𝐹𝑅𝑇+0.0365 × 𝜎 × 𝑒−𝑉𝐹𝑅𝑇 . The factor 
𝜎 is further defined by 𝜎=1
7
(𝑒[𝑁𝑎+]𝑜67.3 − 1), and shows that the voltage dependence can be 
further modified by extracellular Na+ concentration. In our case, the maximum Ip current, 𝐼𝑝� , 
is set to 1.88 pA/pF based on the maximum calculated from our own Ip vs. [Na+]i plot (Figure 
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 1D), instead of the 1.5 pA/pF from the publication. All other parameter values are replicated 
from the original publication or given by experimental conditions: 𝐾𝑚,𝑁𝑎𝑖= 10mM, 
𝐾𝑚,𝐾𝑜=1.5mM, [K+]o =5.4mM, [Na+]o=140mM,  [Na+]i is 10mM for the basal condition and set 
at 11.2mM to simulate effect of 2-meSATP treatment.  
INCX is defined by the equation 𝐼𝑁𝐶𝑋 = 𝑘𝑁𝐶𝑋 × 1𝐾𝑚,𝑁𝑎3 +[𝑁𝑎+]𝑜3 × 1𝐾𝑚,𝐶𝑎+[𝐶𝑎2+]𝑜 ×
1
1+𝑘𝑠𝑎𝑡×𝑒[(𝜂−1)𝑉 𝐹𝑅𝑇] �𝑒(𝜂𝑉 𝐹𝑅𝑇)[𝑁𝑎+]𝑖3[𝐶𝑎2+]𝑜 − 𝑒[(𝜂−1)𝑉 𝐹𝑅𝑇][𝑁𝑎+]𝑜3[𝐶𝑎2+]𝑖�. Keeping all appropriate 
concentration values, half saturation constants,c and the original values for η and 𝑘𝑠𝑎𝑡 (which 
are the voltage dependence and negative potential saturation factors for INCX respectively), 
an overall scaling factor 𝑘𝑁𝐶𝑋 was estimated to fit our INCX data using a least squares fitting 
method in Excel.  
 
2.2.6 Materials 
           KB-R7943, 2-[2-[4-(4-nitrobenzyloxyl)phenyl]ethyl]isothiourea, and 2me-SATP, 2 
methylthio-ATP, were obtained from Sigma Aldrich, Corp (St. Louis, MO, U.S.A). YM-244769, 
N-(3-aminobenzyl)-6-{4-[(3-fluorobenzyl)oxyl]phenoxy} nicotinamide, was obtained from 
Tocris Bioscience (Bristol, United Kingdom).  
c Glossary of Equation Terms and Values 
F Faraday constant, 96,500 coulombs/mol  
𝑓𝑝 voltage-dependence parameter of Ip 
𝜎 [Na+]o-dependence parameter of 𝑓𝑝 
η Factor controlling voltage dependence of INCX, 0.35 
𝑘𝑠𝑎𝑡 Saturation factor for INCX at very negative potentials, 0.1 
𝐼𝑝�  Maximum Na+-K+ ATPase current 
𝐾𝑚,𝐾𝑜 K+ half-saturation constant for Ip, 1.5mM  
𝐾𝑚,𝑁𝑎𝑖  Na+ half-saturation constant for Ip, 10mM 
𝐾𝑚,𝑁𝑎 Na+ half-saturation constant for INCX, 87.5mM 
𝐾𝑚,𝐶𝑎 Ca2+ half-saturation constant for INCX, 1.38mM 
𝑘𝑁𝐶𝑋  Scaling factor of INCX 
R gas constant, 8.314 J/(°K×mol) 
T absolute temperature, °K 
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 2. 3 RESULTS 
2.3.1  Agonist activation of P2X4R increased peak Ip 
Na+-K+ ATPase activity was measured in P2X4R OE ventricular myocytes using the protocol 
described in Figure 1A. Thus, 3 µM 2-meSATP induced an inward current (1.4 ±0.36 pA/pF) 
in 11 of 17 P2X4R OE myocytes (from 9 P2X4R OE mice) confirming our previous results.47  
In these myocytes, the effect of P2X agonist on Ip was determined with 10 mM pipette [Na+] 
(Figure 1B).  In response to 3 µM 2-meSATP, Ip peak increased to 0.58±0.03 pA/pF from a  
Figure 2.1 Peak Na+-K+ ATPase current increases after 2-meSATP application in P2X4 
receptor-overexpressing cardiac myocyte. (A) Upper panel shows rapid solution change 
protocol with 5.4mM [K+]o to elicit K+-activated Ip; lower panel is membrane voltage.  Ip is 
recorded at -20mV and 2me-SATP was applied at -80mV. CTR: control; WO: washout. (B) 
upper panel: individual traces in a typical myocyte showing the increase of [K+]o -activated Ip 
after 2me-SATP application; lower panel: superimposed traces of Ip in control and in 2me-
SATP. (C) Peak Ip, normalized by cell capacitance, is presented as mean±SEM. The 
average control peak Ip differed from that with 2me-SATP. (D) Relationship between peak Ip 
and pipette [Na+].  Peak Ip was elicited by switching [K+]o from 0 to 5.4mM at -20mV; pipette 
Na+ was varied as shown. Normalized peak Ip is presented as mean±SEM.  The number of 
cells is indicated in the parentheses (from 18 P2X4R OE mice). 
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 baseline value of 0.52 ±0.02 pA/pF (P<0.05, Figure 1C), consistent with increased K+-
activated Na+ pump activity. We next estimated the increase in intracellular Na+ that could 
result from the P2X agonist-mediated increase in Ip. To do this, stepwise increments of 
pipette [Na+] were made and increases in Ip determined (Figure 1D). The data describing the 
relationship between pipette [Na+] and Ip were fitted by the Hill equation where I=Imax * 
[Na+]ph/(Kdh + [Na+]p h) and [Na+]p is Na+ concentration in the pipette. The Kd value for [Na+] 
from the equation was 17.6mM, similar to the value obtained by others.69 Accordingly, back 
calculating from this equation, the 0.06±0.01 pA/pF net increase in peak Ip would correspond 
to a 1.08±0.27mM increase of intracellular Na+ during agonist application.  
 
2.3.2  P2X agonist enhances Ca2+ entry mode of INCX 
The NCX current is known to be Ni2+-sensitive,61 and was isolated in this manner 
after taking measures to block other large currents of the cell. After recording the baseline 
Ni2+-sensitive current, 3µM 2me-SATP was applied to myocytes held at -80mV for 3-4 min. 
An inward current was observed in 10 of 15 P2X4R OE myocytes (1.3±0.41pA/pF, from 8 
P2X4 OE mice, Figure 2A). These 10 myocytes were further tested for an effect of the P2X 
agonist on INCX by rapidly adding 10mM NiCl2 to calculate the Ni2+-sensitive current in the 
presence of 2me-SATP.  Data in Figure 2 B and C show that 2-meSATP caused an increase 
in Ni2+-sensitive current at positive potentials (0.55±0.09 pA/pF at control vs 0.82±0.14pA/pF 
with 2-meSATP at 50mV, P<0.05).  The P2X agonist had minimal effect on INCX at the 
negative potentials (-0.46±0.06 pA/pF at control vs -0.45±0.05pA/pF with 2-meSATP at -
80mV).  These data indicate that 2-meSATP caused an increase of INCX, notably in its Ca2+ 
entry mode, helping extrude Na+ in exchange for Ca2+.  
           From the I-V relationships of Ni2+ -sensitive currents, the reversal potential of INCX 
shifted from -14±2.3mV under control condition to -25±4.1mV in response to 2-meSATP in 
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 these myocytes.  We next calculated the change of intracellular Na+ that would cause such a 
shift of the INCX reversal potential from the following equations. 
ENa-Ca = 3*ENa-2*ECa 
ENa= (RT/F)*ln[Na+]o/[Na+]i 
ECa=(RT/2F)*ln[Ca2+]o/[Ca2+]i  
In the calculation, the intracellular resting Ca2+ was artificially kept at 100 nM.  With a 
negative shift of approximately 11±3.52 mV in the reversal potential of INCX after 2-meSATP, 
intracellular Na+ sensed by the NCX would need to increase by 1.28±0.42 mM, provided that 
[Na+]i before agonist treatment was 10mM as was provided in the pipette solution. If the 
resting Ca2+ were presumed to be 50 nM, the intracellular Na+ sensed by the NCX would still 
increase by 1.0±0.34 mM. The subsarcolemmal [Ca2+]i is difficult to estimate even if there is 
10 mM EGTA in the pipette solution. This is due to the fact that EGTA is relatively ineffective 
in buffering Ca2+ within 20-100 nm of the pore 72. Under the physiological condition of a living 
cardiac myocyte, 2-meSATP may cause an increase, even small, of intracellular Ca2+ level 
via a direct calcium entry through the P2X4R. Under this circumstance, the estimated 
1.28±0.42 mM increase of Na+ in the subsarcolemmal space might be under-estimated. 
Overall, while we could not be certain of the exact subsarcolemmal Ca2+ level, whatever the 
presumed level of Ca2+, [Na+]i would have to increase to cause the observed shift of NCX 
reversal potential. The fact that this estimate from NCX measurements is remarkably similar 
to that obtained from Ip measurements provides additional confidence in the value obtained. 
To verify that 2-meSATP increases Ca2+ entry mode INCX, the Ni2+-sensitive current 
was measured at a holding potential of +30mV without running the ramp protocol before and 
after 3 µM 2me-SATP application (Figure 2D). At 30 mV, the Ni2+-sensitive current increased 
from 0.28±0.04pA/pF in control condition to 0.48±0.06pA/pF (P<0.05) after 2me-SATP 
(Figure 2E). Thus, by either voltage ramp or step, P2X agonist elicited an increase in Ca2+ 
entry mode INCX. 
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Figure 2.2 Calcium entry mode of Na+-Ca2+ exchanger is increased with 2-meSATP.   
INCX, represented by Ni2+-sensitive current, in P2X4R OE ventricular myocytes was 
determined. (A) Representive trace is shown for membrane current when 10mM Ni2+ was 
applied (time period bracketed by down and up arrows) under control conditions, during 
2me-SATP application and after washout (WO). (B) Upper panel: descending voltage ramps 
from 80mV to -100mV were used to contruct the I-V relationship. Lower panel: typical traces 
of membrane currents are shown in control (CTR) and in the presence of Ni2+. (C) Mean I-V 
relationships of the Ni2+-sensitive current in control (filled squares) and in the presence of 
2me-SATP (open circles). *P<0.05, N=10 from 8 P2X4R OE mice.  (D) 2me-SATP increases 
Ca2+ entry mode INCX. Representative traces were shown for the Ni2+ -sensitive currents at 
+30mV before and after 2me-SATP application in a P2X4R OE myocyte. E:  Plot of Ni2+-
sensitive current at +30mV at control and during 2me-SATP application (P<0.05 N=7 cells 
from 5 P2X4R OE mice)  
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 2.3.3 Simulated I-V relationships 
The experimental data indicate that elevation of [Na+]i by P2X4R activation results in 
an increase of Ip and of INCX.  We asked whether a simulated rise in [Na+]i of the same 
magnitude can cause an increase of Ip and INCX like that observed experimentally in P2X4R 
overexpressing myocytes. In simulations (see Methods), when the cellular Na+ was 
increased by 1.2 mM, a magnitude similar to that estimated by the experimentally measured 
stimulation of INCX or Ip by 2-me-SATP, the predicted I-V relationship of Ip matched closely 
the experimentally observed increase in Ip (Figure 3A). Similarly, the computationally derived 
I-V relationship of INCX agreed well with our experimental results (Figure 3B). Thus, based on 
established mathematical models for NCX and Na+ pump,71 the increase in [Na+]i and its 
corresponding stimulation of INCX and Ip agreed well with our experimental results.  
We modified the scaling factor from 1.5 pA/pF in the original equation for Ip model71 
to our experimentally measured maximum Ip current at 1.88 pA/pF. In the computerized 
model, Ip is outwardly directed over the entire test potential range (-80 to +50 mV) and is 
increased following a 1.2 mM increment of intracellular Na+ (Figure 3A). At -20 mV, the 
predicted increase in Ip, 0.04 pA/pF, is similar to the experimentally determined increase of 
0.06±0.01 pA/pF following stimulation by 2me-SATP.   
In the modeling of INCX, the best fit for our experimental INCX data led us to use a kNCX 
of 2606.64 pA/pF instead of 2000 pA/pF used by others.71  The modeled I-V relationship of 
NCX shifted leftward upon the 1.2mM step increase of intracellular Na+ from 10 mM to 11.2 
mM.  This leftward shift was not a parallel change since the primary effect was an increase 
in Ca2+ entry mode of INCX with little if any change of the Ca2+ exit mode. The computationally 
simulated shift of the I-V curve for INCX was similar to the experimentally observed shift by 2-
meSATP (Figure 3B). At +50 mV, the modeled Ca2+ entry mode increased from 0.60 pA/pF 
at 10mM [Na+]i to 0.86 pA/pF at 11.2mM [Na+]i (0.26 pA/pF net increase).  This modeled 
increase agrees well with that observed experimentally (0.27±0.10 pA/pF net increase, 
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 Figure 2C). Overall, an elevated intracellular Na+ level has a more detectable effect on the 
Ca2+ entry rather than the Ca2+ exit mode of INCX. 
 
Figure 2.3 Simulated I-V relationships with intracellular [Na+] change.  (A) Simulation for 
Ip with [Na+]i taken as cellular (pipette) Na+ of 10 mM (solid line) and 11.2 mM (dotted). (B) 
Simulation for INCX with [Ca2+]i kept constant at 100nM for cellular Na+ of 10 mM (solid line) 
and 11.2 mM (dotted). The actual experimental data under control (solid squares) and after 
2me-SATP application (open circles) were also plotted for comparison to the simulation. 
 
2.3.4 KB-R7943 or YM 244769 inhibits 2me-SATP-induced increase of cell shortening 
Extracellular 2-meSATP increases CS in P2X4R OE cardiac myocytes.51  To explore 
if the Ca2+ entry mode of NCX contributes to the increase of CS by 2-meSATP in P2X4R OE 
cardiac myocytes, KB-R7943 and a structurally different NCX inhibitor YM 244769,73 which 
preferentially oppose the Ca2+ entry mode, were tested in P2X4R OE myocytes.  KB-R7943 
at 5 µM or YM-244769 at 0.1 µM did not alter the basal cell shortenings of the P2X4R OE 
myocytes (total of 19 myocytes from 7 P2X4R OE mice, Figure 4B), similar to previous 
observation.74 It was shown that while NCX-mediated Ca2+ influx could be blunted with 5µM 
KB-R794, baseline contraction remained unaffected.74 Superfusion with 3 µM 2me-SATP 
increased CS by 29.2±3.7% above basal in 16 of 23 P2X4R OE cardiac myocytes paced at 
0.5 Hz (P<0.05, from 10 P2X4R OE mice). When 5 µM KB-R7943 was added in the 
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 continued presence of 2me-SATP, the increase of CS was reduced to 13.8±3.9% above 
basal (P<0.05, Figure 4A and 4C). In another set of similar experiments, we tested the effect 
on 2-me-SATP-stimulated CS by YM-244769. In these studies, 3 µM 2me-SATP increased 
CS by 31.4±7.1% in 10 of 15 P2X4R OE cardiac myocytes paced at 0.5 Hz (P<0.05, from 6 
P2X4R OE mice). At 0.1 µM, YM-244769 reduced the 3 µM 2me-SATP-stimulated CS to 
17.3±7.4% above basal (P<0.05, Figure 4D). Thus, either KB-R7943 or YM-244769 could 
inhibit the 2me-SATP-induced increase of CS, indicating a role of NCX Ca2+ entry mode in  
 
Figure 2.4 Preferential calcium entry mode blockers of the Na+-Ca2+ exchanger inhibits 
2me-SATP-induced increase of cell shortening.  (A) Representative traces of cell 
shortening (CS) in P2X4R OE myocytes paced at 0.5 Hz are shown for cells exposed to 
2me-SATP and then to 2me-SATP plus KB-R7943 (KBR), followed by washout. (B) Basal 
CS did not change after application of KB-R7943 (N=12) or YM-244769 (N=7). (C) Percent 
increases of CS above basal during application of 2me-SATP alone (N=16 cells, 10 P2X4R 
OE mice) was blunted during addition of KB-R7943 plus 2me-SATP. (D) Percent increases 
of CS above basal during application of 2me-SATP alone (N=10 cells, 6 P2X4R OE mice) 
was higher than that during exposure of YM-244769 (YM) plus 2me-SATP. P<0.05 for all bar 
indicated pair comparisons in panels C & D.  
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 mediating the P2X agonist effect on myocyte contractility in these P2X4R OE myocytes. 
 
2.3.5 P2X agonist can stimulate INCX in WT ventricular myocytes 
To explore the physiologic relevance of this receptor in modulating Na+ handling,   
the effect of P2X agonist on INCX and myocyte contraction were tested in cardiac ventricular 
myocytes from WT mice. Application of 10 µM 2me-SATP induced an inward current at -
80mV (0.68±0.26pA/pF) in 8 of 34 WT ventricular myocytes (from 7 WT mice), similar to our 
previous findings.47 These P2X agonist-responsive myocytes were then tested for changes 
in INCX.  2me-SATP increased Ni2+-sensitive current at positive potentials (0.46±0.05 pA/pF at 
baseline vs 0.59±0.06pA/pF with 2me-SATP at +50mV, P<0.05, Figure 5A). There was no 
significant change induced by 2me-SATP in Ni2+-sensitive current at negative potentials (-
0.40±0.09 pA/pF at control vs -0.42±0.09pA/pF with agonist at -80mV, P>0.05). The primary 
effect on the Ca2+ entry but not the exit mode of NCX in WT myocytes is essentially the 
same as that found in myocytes from P2X4R OE hearts. The reversal potential of INCX shifted 
from -13.25 ±1.72 mV to -17.5±1.29 mV in response to 2me-SATP (P<0.05). These data 
demonstrate that P2X agonist can also elicit an increase in NCX Ca2+ entry mode in some 
WT myocytes.  
As further evidence for a physiological role of cardiac P2X4 receptors, the effect of 
KB-R7943 on the P2X agonist-induced increase of CS was tested in WT murine cardiac 
myocytes. In WT myocytes, P2X agonist has little or no effect on basal contraction. To 
facilitate detection of an agonist-stimulated effect on CS in WT myocytes, 3 µM ivermectin, 
which selectively potentiates the P2X4 effect,63 was combined with 10 µM 2me-SATP. The 
combined presence of 2me-SATP and ivermectin increased CS by 14.8±3.1% above basal 
in 8 of 32 WT paced at 0.5 Hz (P<0.05, from 7 WT mice). Adding 5 µM KB-R7943 to 2me-
SATP plus ivermectin reduced the CS to 7.2±2.3% above basal (Figure 5B, P<0.05), similar 
to the response elicited by KB-R7943 in the P2X4R OE myocytes. The data support a role of 
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 Ca2+ entry NCX mode in mediating the P2X4 receptor-induced increase of CS in WT 
myocytes.   
 
Figure 2.5 The link between P2X receptors and NCX in WT myocytes. (A) 2me-SATP-
induced increase of INCX in WT myocytes. Ni2+-sensitive currents before and after 2me-SATP 
application are presented at membrane potentials of -100, -80 , 50 and 70mV.  INCX at +50 
mV and +70mV were significantly larger in the presence of 2me-SATP than in control 
(*P<0.05, N=8 cells, 7 WT mice). (B) Percent increases of CS above basal were shown 
during application of 2me-SATP plus ivermectin (Ive) (N=8 cells, 7 WT mice) and during the 
subsequent exposure of KB-R7943 (KBR) plus 2me-SATP and Ive (% above basal with KBR 
plus 2me-SATP and Ive vs that by 2me-SATP plus Ive, P<0.05). 
 
 
2.4 DISCUSSION  
Belonging to a family of ligand-gated ion channels, P2X4 receptors are an important 
subtype of the endogenous P2X receptor channel in the cardiac myocyte.  When activated 
by extracellular ATP, these channels conduct cations in a voltage-dependent manner with a 
reversal potential near 0 mV.63, 64 As a Na+ entry pathway, these channels may have a 
physiological role in regulating cellular Na+ levels in cardiac myocytes. The objective here 
was to test the hypothesis that activation of these channels by extracellular ATP causes an 
increased cellular Na+ level in cardiac myocytes. We further determined whether the P2X 
receptor-induced stimulation of NCX has a role in modulating the contractile state of cardiac 
myocytes.  
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 In the present study, we used myocytes from both P2X4R OE and WT mice to test 
these concepts, which are supported by the following lines of evidence. First, the P2X 
receptor-mediated increase in Na+ entry into the myocyte47 should stimulate Ip because the 
pump functions to extrude intracellular Na+. Indeed, activation of the P2X4R by its agonist 2-
meSATP was able to increase Ip in P2X4R OE cardiac myocytes. Second, P2X agonist 
should stimulate INCX, another cellular mechanism for Na+ extrusion. We found that in both 
WT and P2X4R OE cardiac myocytes, 2-meSATP could stimulate the Ca2+ entry mode of 
NCX. Third, an increase in [Na+]i due to P2X receptor-mediated Na+ entry can be estimated 
in P2X4R OE myocytes. For Ip, which was only measured in P2X4R OE myocytes, the 
magnitude of [Na+]i increase, 1.08±0.27 mM, was calculated based on responses calibrated 
to concentration changes in pipette and hence in cytosolic Na+.  For INCX, the receptor-
mediated shift of reversal potential yielded a 1.28±0.42 mM Na+ increase, assuming a 
constant intracellular [Ca2+].  These data provided experimental evidence under voltage 
clamp condition that stimulation of P2X receptors can result in measurable cellular Na+ 
increases.  Fourth, computational modeling, assuming an increment of [Na+]i like that 
observed experimentally, replicated the experimental findings and permitted estimation of 
the pattern and magnitude of increases in Ip and INCX. The simulated effects on Ip and INCX 
from the increase in [Na+]i were similar to previously established dependencies of these 
currents on ionic concentrations and voltage.  Experimentally, the activation of the P2X4 
channel primarily increased the Ca2+ entry mode of NCX. Computationally simulated INCX I-V 
relationship in response to a similarly increased cellular [Na+] also showed an increase in 
only the Ca2+ entry mode. There was minimal effect on Ca2+ exit mode of NCX in the 
simulation. Overall, the computer simulation agreed with experimental data regarding the 
cellular ionic effects on Ip and INCX. P2X agonist also induced a similar pattern of increase in 
Ca2+ entry mode of NCX in cardiac ventricular myocytes of WT animals, supporting a 
physiological role of the cardiac P2X receptor in regulating Na+ handling.  
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 We attempted to measure directly the [Na+]i in P2X4R OE myocytes using the 
fluorescent Na+ indicator SBFI.  We could not detect any change in the intracellular Na+ 
concentration after 2me-SATP application in P2X4R myocytes (data not shown). This is not 
surprising given that the amount of cellular Na+ increase is below the sensitivity of this Na+-
sensitive dye, the Kd of which is 3.8mM in the absence of K+ and 11.3 mM in the presence of 
physiological concentrations of K+ (Molecular Probe website). Swift et al observed that a low 
concentration of ouabain (0.3 µM) increased contractility by 40% via its selective inhibition of 
the α2-isoform of Na+ pump but they could not detect an increase in global [Na+]i by SBFI in 
rat cardiac myocytes.75 They concluded that the increased contractility in response to 0.3 µM 
ouabain could not be explained by a substantial global rise in [Na+]i. Similar to our finding of 
a P2X agonist-induced stimulation of NCX, a local accumulation of [Na+]i after ouabain was 
detectable by INCX measurements.75 It is thought that the Na+ concentration in the 
subsarcolemmal space is sensed by the Na+ pump, NCX, and other membrane transport 
mechanisms.76-78 It is possible that the increase in INCX or Ip measured during cardiac P2X4R 
activation reflects an increase in the subsarcolemmal Na+ concentrations.  
In studying the role of NCX in mediating the P2X receptor-induced effect on 
contraction, we used P2X4R-overexpressing cardiac myocytes. The P2X4R OE myocytes 
displayed a greater magnitude of P2X receptor-mediated increase in contraction and were a 
better model to determine the mechanism of contractile effect of P2X agonist. We postulated 
that Ca2+ entry mode of NCX, stimulated by intracellular Na+ elevation, contributes to 
contraction increase by P2X agonist.  This postulate is supported by our finding that P2X 
agonist was able to enhance sarcoplasmic reticulum Ca2+ content in P2X4R OE myocytes.55 
In the present study, KB-R7943 could inhibit the 2me-SATP-induced increase in CS in 
P2X4R OE myocytes. KB-R7943, at 5 µM, can serve as a selective Ca2+ entry mode 
inhibitor.74, 79 Another structurally different selective inhibitor of the Ca2+ entry mode, YM-
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 244769,73 was also able to inhibit the 2me-SATP stimulation of CS in the P2X4R OE cells. 
Neither KB-R7943 nor YM-244769 affected the basal CS in these cardiac myocytes.   
Several considerations deserve to be mentioned. Ca2+ may enter directly through the 
P2X4R, and could contribute as much as 8% of the total inward current induced by ATP via 
the human homotrimeric P2X4R.65 Direct Ca2+ entry via the P2X receptor may impact 
dynamically the cellular Na+ by further increasing the accumulation of Na+ that enters 
through the receptor under physiological condition in myocytes. We could not exclude that 
P2X agonist increases subsarcolemmal [Ca2+]i via direct calcium entry through the receptor 
channel. A direct measurement of subsarcolemmal [Ca2+]i during P2X agonist stimulation 
was not feasible in the present study.   
 Another implication of P2X receptor activation merits further consideration.  That 
both INCX and Ip can extrude the P2X receptor-mediated Na+ entry distinguishes the P2X 
effect from the contractile and pro-arrhythmic effects of digitalis.  Digitalis, by inhibiting the 
Na+-K+ ATPase and thus causing an increase in intracellular Na+, results in NCX as the only 
Na+ extruding mechanism in digitalis-treated cardiac myocytes.  Since both INCX and Ip can 
operate to extrude P2X receptor-conducted Na+ entry, the cell is less likely to be overloaded 
by intracellular Na+ and Ca2+ during stimulation of P2X receptors. Finally, the physiological 
relevance of cardiac myocyte P2X receptor is supported by the demonstration in WT cardiac 
myocytes that P2X agonist can stimulate NCX and that inhibition of Ca2+ entry mode of NCX 
could reduce P2X4 receptor-induced contraction in these cells.   
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 Chapter 3  
P2X Agonism leads to Limited Cardiac Myocyte 
Excitability 
 
3.1  INTRODUCTION 
As discussed earlier and demonstrated in the previous chapter, P2X receptors allow 
passage of cations, the majority of which are Na+, into cells. They are thus capable of causing 
depolarization and calcium increase in many cell types to initiate signaling. The consequence of 
this seemingly simple event becomes more difficult to envision when imposed on a cardiac 
myocyte, whose function uniquely relies on tightly regulated cycles of action potential (AP) firing 
and calcium transients. How these highly dynamic cycles are affected by the relatively slower 
changing P2X current is not well characterized.  
We have shown that P2X driven electrophysiological changes can underlie an 
enhancement of contraction in cardiac myocytes, and this may be important in maintaining 
cardiac pump function during ischemic injury and in the critical period after injury. 
Overexpression of P2X4R protects against calsequestrin overexpression-induced and post-
infarct heart failure.1, 52 On the other hand, inward cation passage can increase cellular 
excitability and lead to spontaneous activity that is undesirable for the controlled rhythm of the 
heart. There exists a conceptual gap regarding how inotropic enhancement may occur without 
significant electric disturbance. Here we consider the dynamics of P2X activation and study its 
impact on cardiac function in an integrated framework of excitation contraction coupling.  
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 3.2  MATERIALS AND METHODS 
 
3.2.1 Computational Simulation of the P2X current in the context of a Single Cardiac 
Myocyte 
  An ordinary differential equation-based model of the mouse cardiac myocyte, previously 
developed by Bondarenko, et al15 was implemented in the Virtual Cell simulation software80 and 
modified to include an additional flux representing the P2X channel. The simulated P2X current 
follows the general shape of the previously determined I-V relationship47 (Figure 3.1A) and is 
desensitized with an exponential function with modifiable time constant. Simulations were run 
for 1000s with 1Hz pacing for values to reach relative steady state, and the end results were 
copied into new simulations as initial values. VCell outputs for select model parameters were 
exported and plotted.  
 
3.2.2 Animals 
 P2X4 receptor overexpression (P2X4R OE) mice were generated and bred as previously 
described.51, 55, 66 All animal handling protocols have been approved by the Institutional Animal 
Care and Use Committee at the University of Connecticut Health Center. 
 
  3.2.2.1 P2X4R Knockout Animals 
The Cre-Lox recombination technology was employed for P2X4R gene targeting.81  The 
first loxP site was inserted into intron 4 and the second loxP site together with the Frt-PGKneo-
Frt cassette was inserted in intron 1, in a direction opposite to the transcription of P2X4R. The 
targeting vector was electroporated into embryonic stem cells, which were derived from F1 
(129Sv/C57BL6J) blastocysts. Chimeric animals were generated by aggregating targeted ES 
cells with CD1 morula. The PGKneo cassette was removed by breeding chimeric males with 
ROSA26-Flpe females (Jax stock no: 009086) to generate P2X4floxed/+ F1 pups. F1 mice were 
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 backcrossed with C57BL6 mice for over ten generations to produce P2X4floxed/floxed mice in the 
C57BL6 background.  
Homozygous P2X4floxed/floxed males were then bred with heterozygous females with 
widespread expression of the Cre recombinase, including in the unfertilized egg (129S1/Sv-
Hprttm1(cre)Mnn/J; Jax stock no. 004302 bred to the C57BL6 background) to produce P2X4floxed/+ F1 
pups with Cre-excised floxed gene, which were crossed together to generate homozygous 
global P2X4R knockouts. Genotyping was carried out using primers listed in Appendix A Table 1, 
and immunoblotting confirmed protein decrease.    
 
3.2.3 Measuring Voltage with Single Cell Patch Clamp 
Myocytes from 8-16 week old WT and P2X4R OE mice were obtained and placed in a 
small superfusion chamber on the stage of an inverted microscope. For isolation procedure, 
refer to Section 2.2.1. Rod-shaped myocytes with clear striations and without spontaneous 
contraction are considered healthy cells for experimentation. Whole-cell patch clamp was 
established with a K+-based pipette solution (in mM: 120 potassium aspartate, 30 KCl, 5 
Na2ATP, 1 MgCl2, 10 HEPES, and 10 EGTA, pH 7.3 adjusted with KOH) to maintain 
physiological internal conditions for subsequent voltage examination. 2-meSATP or control 
buffer solution was given via rapid perfusion (SF-77B, Warner Instrument) to quiescent or 
stimulated (action potentials elicited with current injection) cardiac myocytes in current-clamp 
mode. Generation of protocols and acquisition of data were carried out in pCLAMP10 (Axon 
Instruments). For characterizing initial depolarization in response to P2 agonism, each cell was 
only exposed to 2-meSATP once to avoid desensitization effects. In a subset of experiments, 2-
meSATP was withdrawn after some time to establish washout of drug, where as in other 
experiments 2-meSATP was delivered continuously for 10 minutes to examine natural 
desensitization.  
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 3.2.4 Ex Vivo Working Heart for monitoring Whole Heart Function 
Mice 8-16 weeks in age from both sexes were anesthetized with a ketamine/xylazine 
mixture before the chest was opened and the heart, with all major vessels and lungs attached, 
excised for immediate cannulation of the aorta. The viability of the heart was maintained with 
oxygenated Krebs-Henseleit bicarbonate buffer (in mM: 119 NaCl, 25 NaHCO3, 4 KCl, 1.2 
KH2PO4, 1 MgCl2, 1.8 CaCl2, 10 glucose and 2 Na-pyruvate; pH adjusted to 7.4 by bubbling with 
95% O2 and 5% CO2) in the Langendorff mode while the pulmonary vein was cannulated and a 
pressure transducer was inserted into the left ventricle. After the heart was stably mounted, 
retrograde perfusion through the aorta was switched to antegrade perfusion via the pulmonary 
vein, establishing the working heart mode. The afterload against which the perfusate is ejected 
from the left ventricle was set to be constant with a column of buffer connected to the aorta. 
Hemodynamic parameters were derived from digitized pressure traces and analyzed in 
LabChart Pro (ADInstrument). In a number of experiments, electrodes were placed at the right 
atrium and left ventricle for a 2-lead electrical rhythm recording. After a stabilizing period with 
drug-free perfusate, 2-meSATP of a given concentration between 10nM to 100uM was 
administered for 10 minutes. Hearts were allowed to beat at their intrinsic pace. Those with 
baseline heart rate under 250 beats per minute were excluded from further experimentation. 
Additional experiments were performed on P2X4R KO hearts at 1µM of 2meSATP to further test 
differences seen between WT and P2X4R OE animals.  
 
3.2.5 Quantification of Ectopic Activity 
  Abnormal beats were detected using the heart rate variability module of LabChart Pro. 
Deviations from normal heart rate are easily visualized using the tachogram, which plots 
successive R-R intervals over time. Ectopic beat detection was confirmed with visual inspection 
of the tachogram and the raw recording trace. The numbers of ectopic beats 10 minutes before 
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 and after drug application were recorded. Hearts with greater than 5% of its baseline beats 
classified as abnormal were excluded from further analysis. 
  
3.2.6  Data Analysis and Statistics 
 Patch-clamp data were analyzed using Clampfit 10.0 (Molecular Devices, CA, USA) and 
exported to GraphPad Prism for graphs. Pressure traces from isolated working hearts were 
analyzed in LabChart Pro. Pressure parameters from beat cycles were averaged every 5 
seconds, and data were normalized to 4 minutes before drug application for percent change 
from baseline. Data are reported as mean ± standard error of the mean (SEM). Paired t-test 
was used to compare drug effects, and differences between genotypes were compared with two 
tailed, unpaired t-tests. The level of significance is taken as being P<0.05.    
 
3. 3 RESULTS 
 
3.3.1 Computational modeling predicts enhanced cardiac myocyte excitability with P2X 
activation  
Simulations demonstrated that P2X activation can evoke a spectrum of outcomes for 
calcium transients that result in its eventual enhancement, consistent with the suggestion that 
P2X activation can enhance contraction in cardiac myocytes. However, the initial cellular 
response can be variable, depending on P2X current characteristics and other cellular factors. 
Select simulation outputs are displayed in Figure 3.1. The P2X current was assumed to be 90% 
carried by Na+ and 10% by Ca2+ ions, and the desensitization constant was assumed to be 60 
seconds in these simulations.  Mimicking turning on the P2X current at 150 seconds into the 
simulation in WT cardiac myocytes (Figure 3.1A open circles showing previous experimental 
data for WT, and solid data illustrating simulated I-V relationship for a representative WT 
myocytes), AP generation was not significantly altered except for a slight initial depolarization,
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Figure 3.1   Computational predictions of P2X induced action potential and calcium changes. (A) Simulated I-V curves as 
compared to previously experimental data from WT (open circles, simulated results in solid line) and P2X4R OE (closed circles, 
simulated results in dashed line) cardiac myocytes. (B) Simulated cardiac myocyte response to activation of P2X current in WT 
cardiac myocyte showing slight resting membrane depolarization that does not disrupt action potential generation and gradual 
enhancement in calcium transients. (C) Simulated voltage and calcium response to activation of current in P2X4R OE cardiac 
myocyte. Membrane depolarization is large enough to initially blunt normal AP generation and calcium cycling, but normalizes over 
time.  
 
 
 while corresponding calcium transient trace demonstrate increase over baseline (Figure 
3.2B). At a conductance level similar to what we measured previously in the P2X4R OE 
cardiac myocytes (Figure 3.1A closed circles and dashed line), opening of the P2X channel 
can lead to an initially large depolarization from rest, temporarily attenuating stimulated APs 
and beat-to-beat calcium cycling (Figure 3.1C). A number of ectopic action potentials are 
seen in the simulation data, due to partial opening of fast Na+ channels. But given that the 
P2X receptor desensitizes, these disruptions are transient and enhanced calcium transients 
were observed when APs normalized. These results are in contrast to our earlier conclusion 
that activation of the P2X4 current does not alter cellular excitability, which was based on 
observations that P2X4R OE myocytes exposed to 3 minutes of 3µM of 2-mesATP bath 
perfusion had no significant change in action potential characteristics at that time point.55 
Simulation results thus prompted us to re-examine our previous protocol and to retest 
cardiac myocyte excitability and the propensity of arrhythmogenesis in the intact heart in 
response to P2X activation.   
 
3.3.2 P2X4R OE myocytes display transient depolarization in response to activation  
 We performed current clamp experiments with K+-based pipette solutions in order to 
investigate whether inward current activated by 2-meSATP were able to induce changes in 
resting membrane potentials and modulate the excitability of ventricular myocytes. Rather 
than using gravity based bath application of 2-meSATP, we employed a fast switch system 
that allowed us to pinpoint the drug application to a sub-second scale. In resting P2X4R OE 
myocytes, we observed prompt depolarization responses to pulses of 2-meSATP (Figure  
3.2A). Note that none of the subsequent depolarizations were larger than the initial 
depolarization, suggesting that desensitization is observed with each pulse of agonist 
application, which is further supported by the observation that a longer off time between two 
pulses led to greater recovery. More prolonged 2-meSATP application caused immediate  
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 membrane depolarization that slowly normalized over minutes (Figure 3.2B). 
 
 
Figure 3.2   2-meSATP elicits membrane depolarization in P2X4R OE cardiac myocytes.  
(A) Example quiescent myocyte in current clamp mode, measuring resting membrane 
potential and depolarization caused by 5µM 2-meSATP pulses. (B) More sustained 2-
meSATP delivery demonstrating normalizing membrane potential in another quiescent 
myocyte over 3 minutes. (C) and (D) Examples of myocytes, stimulated every 2s to fire an 
action potential. 5µM 2meSATP is administered during action potentials 11 to 20. The 
myocyte in (C) experienced less resting membrane depolarization and action potential 
alteration than the myocyte in (D). Spikes observed during 2-meSATP application in (D) 
likely reflect stimulus current. Overlapped sweep views to the right show difference in action 
potential duration between the two cells, pointing to a likely difference in repolarizing 
capacities. Black line is pre-drug baseline, red corresponds to maximum depolarization, and 
grey line shows recovery. 
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 To better understand the effect of P2X4 channel mediated depolarization on beating 
cardiac myocytes, a 0.5ms current of sufficient magnitude to elicit an action potential (0.5-
2nA) was injected every 2 seconds. Myocytes were recorded for 30 cycles of AP, with 5µM 
2-meSATP applied during AP numbers 11-20. The responses of two myocytes are shown in 
Figure 3.2 C and D, illustrating the variability in the magnitude of resting membrane 
depolarization and effects on action potential generation. While some cells experienced 
small depolarizations, others experienced large (>40mV) depolarizations, which then 
rendered the cell unable to fire APs in response to subsequent current injections. These 
results demonstrate that the purinergic agonist 2-meSATP can trigger immediate 
depolarizations in both quiescent and stimulated cardiac myocytes isolated from cardiac 
specific P2X4R OE hearts. The general features mimic what would be expected from the 
activation of a P2X4 current, namely, fast activation followed by slow desensitization.   
There was a clear difference between the response of P2X4R OE cardiac myocytes 
and that of the WT cardiac myocytes to stimulation with 2-meSATP (Figure 3.3). A 
concentration dependent shift in the proportion of cardiac myocytes that experienced large 
depolarizations in response to the agonist was evident in P2X4R OE myocytes. Out of the 
ten cells exposed to 5µM 2-meSATP, three experienced >40mV depolarizations. The 
average depolarization of these three cells was 49.91±2.05 mV, while the seven cells that 
had smaller responses was 4.20 ±0.98 mV, combining for a total average of 17.92±8.63 mV 
for 5µM 2-meSATP induced depolarization in P2X4R OE myocytes. A closer examination of 
the data suggests that baseline action potential duration may impact myocyte responses to 
purinergic agonism, offering insight into the variable cellular response at this lower 
concentration of agonist. Myocytes that took longer for action potentials to reach 90% 
repolarization (APD90) before drug was added showed greater depolarization in response to 
P2X activation, which may reflect relatively blunted repolarization mechanisms in these cells 
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 (Figure 3.3B). When 100µM 2-meSATP was applied, all tested P2X4R OE cardiac myocytes 
displayed large depolarizations, which averaged 51.67±3.34 mV. The mean magnitude of  
depolarization and the proportion of cells experiencing large depolarization increased with 
increasing concentration of 2-meSATP in the P2X4R OE animals, while the majority WT 
myocytes did not experience an immediate depolarization even at 100µM of 2meSATP 
(0.74±0.53 mV, n=11, p>0.05 against buffer control; individual data points displayed in 
 
 
Figure 3.3   Summary of maximum depolarization in response to 2-meSATP 
2-meSATP elicited depolarization in P2X4R OE cardiac myocytes. Maximum resting 
membrane depolarization in response to 2-meSATP are plotted against baseline AP 
characteristics that may reflect K+ channel activity: (A) Resting membrane potential, and (B) 
the time for action potential to recover 90% (APD90). 3 out of 10 cells experienced large 
depolarizations in response to 5µM 2-meSATP and APD90 may be a good predictor of this 
response. All cells exposed to 100µM 2-meSATP experience large depolarizations. (C) WT 
cardiac myocytes did not significantly depolarize in response to 100µM 2-meSATP. (D) 
Summary of WT and P2X4R OE immediate cellular depolarization in response to P2 
agonism.  
WT 
P2X4 OE P2X4 OE 
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 Figure 3.3C, with insert showing magnified voltage scale).  However, 8/11 of the WT cells 
exposed to 100µM of 2meSATP experienced spontaneous activity at a later point during the 
treatment.  Buffer control did not elicit significant depolarization in either P2X4R OE 
(0.05±0.15 mV, n=5) or WT (0.01±0.20 mV, n=8) cardiac myocytes. These results support a 
P2X4 channel mediated depolarization response to 2-meSATP, with concentration 
dependent change in the population response.     
After establishing that the depolarization response is specific to agonist stimulation of 
the P2X4 receptor, we next asked what would happen in the continued presence of agonist. 
As predicted by the computational model, desensitization of the P2X current would lead to 
normalization of action potential in the continued presence of 2-meSATP, and this was 
corroborated by patch clamp data. In 3 of the 4 P2X4R OE myocytes exposed to 100µM of 2- 
meSATP, current injection stimulated action potential firing resumed after 18, 21 and 34 
seconds (example cell shown in Figure 3.4B; refer to simulation result in Figure 3.1C 
expanded AP graph for comparison). In the other cell where membrane potential did not 
recover, the seal was confirmed to be lost after 3 minute. It should be noted that these 
 
 
Figure 3.4   P2X4R mediated membrane depolarization is transient 
(A) Buffer control had no effect on cardiac myocyte APs. (B) P2X4R activation led to 
membrane depolarization that initially blunted current injection stimulated AP firing but 
recovered over time, with resumption of stimulated APs. Bars indicate presence of treatment 
solutions, which were continually applied for 10 minutes. While the recovered APs shown in 
(B) are of smaller amplitude compared to baseline, this is not representative of the APs later 
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 in time as the P2X current continued to desensitize. A full recovery comparable to baseline 
would be seen later.       
experiments were performed with 10mM EGTA in the pipette solution to buffer intracellular 
Ca2+.  These findings reveal that while 2-meSATP-evoked inward cationic current via the 
P2X4 channel can lead to cellular excitability, direct depolarization effects are temporary.   
 
3.3.3 P2X activation does not increase arrhythmogenesis in Intact Hearts 
 Because cellular electrophysiological data confirmed that P2X4 channel activation 
can rapidly modify myocyte membrane excitability and since others have suggested that P2 
agonism can induce serious ventricular arrhythmias, we sought to more carefully examine 
this arrhythmogenic potential in intact hearts. Isolated hearts were mounted in the working 
heart configuration and allowed to beat at their intrinsic pace. Baseline heart rates were 
similar, at 393.4±6.64 (n=64) and 390.7±6.95 (n=53) beats per minute for WT and P2X4R 
OE hearts, respectively. We did not observe significant arrhythmic activity in P2X4R OE 
hearts as compared to WT at baseline. Eight WT and one P2X4R OE hearts had greater 
than 5% of their baseline beats classified as abnormal, and were excluded from analysis of 
agonist treatment effect. Most ectopic activities took the form of premature ventricular beats 
(Figure 3.5A). Paired t-test comparisons of the effect of 2-meSATP application indicated that 
there was a significant increase in the number of ectopic beats in WT hearts at 10µM and 
100µM of 2-meSATP (Figure 3.5B). There was a trend towards increased ectopic activity at 
the highest concentrations of 2-meSATP in P2X4R OE hearts as well, mainly driven by 3 
hearts that had a noticeable increase (>5%) in the number of abnormal beats, but this 
increase remains statistically insignificant.  These data suggest that 2-meSATP at high 
concentrations can increase ectopic action potentials in WT hearts, but P2X4 channel 
overexpression in cardiac myocytes does not increase baseline and agonist-induced 
arrhythmic activity. 
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Figure 3.5   Summary of Ectopic Activity in Intact Hearts 
(A) Example electrical and pressure trace from a P2X4R OE heart treated with 100µM 2-
meSATP. Arrows mark ectopic events. (B) Summary of the increase in the number of 
ectopic beats after 2-meSATP application for each individual heart. * denotes significant 
increase by paired t-test in WT with 10µM and 100µM of 2-meSATP.  
 
 
3.3.4 A novel biphasic contractile response to 2-meSATP in murine hearts 
In addition to close examination of possible arrhythmic sequelae induced by altered 
cardiac myocyte excitability in whole hearts, the working heart setup allowed us to quantify 
additional parameters associated with pressure development in the left ventricle. Continuous 
2-meSATP treatment led to a surprising, previously undescribed, biphasic response in both 
WT and P2X4R OE hearts (Figure 3.6). Control perfusion did not elicit significant change, 
and 2-meSATP below 1µM had minimal effect. In response to doses of 2-mesATP 1µM and  
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Figure 3.6   2-meSATP leads to dose-dependent biphasic response in the murine heart. 
(A) Raw data trace from an example WT heart, treated with 100µM 2-meSATP. 
Corresponding 5 second averages recorded for WT hearts exposed to 100µM 2-meSATP 
showing percent changes from baseline (bl) in terms of (B) left ventricular pressure height 
and (C) heart rate. (D) The pressure and heart rate product (PH*HR) and (E) the maximum 
rate of pressure development (+dP/dt, black solid line) and maximum rate of relaxation (-
dP/dt, gray dashed line) are shown as surrogates for overall cardiac output. (F-J) Summary 
of biphasic response showing maximum depression and enhancement changes from 
baseline after various doses of 2-meSATP in both WT and P2X4R OE hearts (black circles 
for WT, red circles for P2X4R OE; n=15 for each group exposed to 1µM to 100µM; WT 
hearts treated with 10nM and 100nM had n=10 per group; P2X4R OE hearts at 10nM and 
100nM had n=2 and 7 respectively). (K) Summary of +dP/dt maximum changes from 
baseline at 1µM across hearts of all three genotypes (n=11 for P2X4R KO). *P<0.05 
indicates significant difference between WT and P2X4R OE for F-J and for the indicated 
pairs in K.  
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 greater, an initial drop in pressure was evident, usually occurring within one minute. The 
pressure then recovered and rose higher than the baseline pressure in most cases. Wash 
out of drug returned measures to baseline levels or slightly below baseline due to a natural 
decline of function over time. Both the depressive and enhancement phases were dose 
dependent, and a slowing of heart rate was significant at 100µM of 2-meSATP in both WT 
and P2X4R OE hearts (Figure 3.6 C and G). There was no sign of loss of sinus rhythm.  
A significant difference between WT and P2X4R OE hearts was consistently 
observed at 1µM 2-meSATP, where both the depressive and enhancement phases were 
greater in the WT (Figure 3.6F, H, I, J). Further experimentation on P2X4R KO hearts at this 
concentration of agonist showed that the biphasic response is persistent in P2X4R knockout 
hearts (Figure 3.6K) and was not different from WT response. 1µM 2-meSATP treatment of 
P2X4R knockout hearts led to an initial depression in LV pressure followed by recovery and 
enhancement in a similar time course and to comparable magnitudes as WT hearts.  
Baseline parameters were also not significantly different from WT littermates. The baseline 
PH for P2X4R KO hearts was 90.87±3.66 mmHg (vs. 92.85±2.46 mmHg in WT, n=6) and the 
HR was 379.5±14.35 beats per minute (vs. 374.6±23.55 in WT, n=6).  
 
3.4  DISCUSSION 
Extracellular ATP-activated purinergic receptors have been implicated in different 
physiological and pathophysiological events such as platelet aggregation, hypoxia, pain, and 
vascular diseases. With increasing interest in targeting these receptors for treating various 
aspects of cardiovascular disease, it is important to clarify their effects on cardiac excitability. 
While many studies have described the cardiac effects of ATP, reviewed in 82,  results are 
mixed and remain controversial due to differences in methodology and fast breakdown of the 
extracellular nucleotide. It is difficult to ascertain both the composition and concentration of 
ATP and its metabolites that reach the heart after bolus injections and in vivo data can be 
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 complicated by nerve terminal release of ATP as co-transmitters83, 84 and reflexive responses 
to sympathetic afferents.85 In this study, in addition to examining P2 agonism in WT animals, 
we took advantage of our P2X4R OE transgenic animals to further clarify the effects of 
activating these receptors.  
At the cellular level, we along with other groups have previously demonstrated 
enhanced contraction after 2-meSATP application in a number of studies.42, 49 Others have 
observed spontaneous contractions in quiescent myocytes and ectopic beats in electrically 
stimulated myocytes in response to P2 agonist that suggest altered cellular excitability.46, 86 
Earlier data from our laboratory also established a current-voltage (I-V) relationship caused 
by 3µM of 2-mesATP after 3 minutes of bath perfusion and suggested no significant change 
in action potential at that time point.55 When we incorporated the previously obtained I-V 
relationship into an established murine cardiomyocyte computational model, we observed 
immediate depolarization that, in the case of the current magnitude representing P2X4R OE 
myocytes, was large enough to blunt subsequent action potential firing. Therefore we 
revisited the question of cellular excitability in the P2X4R OE cardiomyocytes with a modified 
protocol. Instead of bath application of agonist, as is done in most studies, we employed a 
rapid perfusion technique that allowed us to precisely determine the timing of drug 
stimulation. With this improved technique we saw immediate depolarization in P2X4R OE 
cardiomyocytes that desensitized with prolonged agonist presence both in quiescent and 
stimulated myocytes (Figure 3.2B and 3.4B). The EC50 and current 
desensitization/resensitization rates of P2X currents in more pure expression systems have 
been reported.63 Comparing the range of these values to our data suggests that our 
observation is P2X4R-specific. P2X1 and P2X3 are desensitized at a much faster rate, while 
P2X5 and P2X6 are thought to have low membrane expression and thus contribute little to 
overall agonist-induced current. P2X7 is uniquely stimulated at higher concentrations of 
agonist and does not desensitize significantly on the minute time scale. P2X2 has similar 
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 characteristics as P2X4, and heterotrimeric combinations of P2X subtypes (P2X1/2, 1/4, 1/5, 
2/3, 2/6, 4/6, 4/7) are plausible contributors as well, as many have a similarly slow rate of 
desensitization or remain uncharacterized.87 However, the lack of response in WT  
cardiomyocytes further suggest that the immediate excitation seen in P2X4R OE myocytes 
were specific to the activation of the P2X4R channel. Considering the desensitization 
characteristics observed in these experiments, it is not surprising that we previously did not 
see changes in action potential characteristics after 3 minutes of treatment. Additionally, the 
previous experiments were performed with 3µM 2-meSATP, which would stimulate a smaller 
population of cells to have large depolarization responses that would significantly affect 
electrically stimulated APs. It is of interest to note that 8 out of 11 WT cells that were 
exposed to 100µM of 2-meSATP spontaneously depolarized at later times during treatment, 
somewhat consistent to findings in other studies.46 The significance and mechanism of these 
ectopic events are unclear.      
After observing that high concentration 2-meSATP stimulation of P2X4 receptors 
resulted in robust immediate depolarizations, we questioned its effects on action potential 
propagation in intact hearts. Somewhat to our surprise, we did not observe increased 
arrhythmic activity in P2X4R OE hearts, even with high concentration 2-meSATP treatment. 
In the WT intact hearts, however, we observed a significant increase in the number of 
ectopic beats after high concentration 2-meSATP treatment. This may be consistent with 
observations from others.  Monophasic action potential recording in Langendorff-perfused 
mouse hearts showed that high concentrations of ATP (10µM and 100µM) can induce 
delayed after-depolarization (DAD) and ectopic APs, which can be blocked with 100µM 
suramin or 30µM PPADS, but not with 10µM nifedipine.86 As nifedipine blocks the L-type 
Ca2+ channel and in turn deplete SR Ca2+ storage, it was suggested that the ATP-induced 
arrhythmic events likely involved Ca2+ influx via purinergic receptors.  Ventricular tachycardia 
(VT) was reported in 3 out of 7 spontaneous beating hearts and in 6 out of 7 hearts that were 
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 perfused with ATP for 20 minutes before being provoked with programmed electrical 
stimulation.86 It is difficult to ascertain the severity of VT in this report given the relatively 
loose definition of VT as three or more successive ectopic beats, but we did not observe any 
sustained VT in our experiments. It is possible that 2-meSATP is less potent than ATP in 
stimulating the subset of P2 receptors responsible for the proarrhythmic activities observed. 
For example, 2-meSATP is a partial agonist of P2X4R receptors with an EC50 of 10 to 
100µM, as opposed to ATP, which has an EC50 of 1 to 10µM.23 Given that the P2X4R is not 
blocked by suramin or PPADS at the concentrations used to prevent ATP-induced 
arrhythmias,23 combined with the fact that  we did not observe increased propensity for 
arrythmogenesis in our P2X4R OE hearts, it is unlikely that the P2X4 receptor played a role in 
the arrhythmias elicited in the earlier report. ADP has also been shown to be 
proarrhythmogenic to a lesser extent, while UTP and adenosine had no effect. This agonist 
profile suggests that in the WT murine heart, P2Y1 and P2Y11 receptors may be involved in 
the increased arrhythmogenesis, as they are linked to phospholipase C and cAMP pathways 
that could increase mobilization of intracellular calcium.88 The P2Y11 receptor has also been 
implicated to be responsible for ATP-induced inotropic increase in murine cardiac 
myocytes.89  Phospholipase related IP3 production can activate IP3 receptors in the SR 
membrane and nuclear envelope, which can modulate excitation contraction coupling by 
sensitizing nearby ryanodine receptors, leading to positive inotropic but also pro-arrhythmic 
effects.90 Since significant overexpression of a P2X channel in the P2X4R OE hearts did not 
show an increased propensity to develop serious arrhythmias even at high concentrations of 
the agonist, it is difficult to imagine how other P2X receptors would be proarrhythmogenic, as 
they would operate similarly in terms of electrophysiology and most others are even faster 
desensitizing or less Ca2+ permeant (except for P2X7 at high concentration agonist). 
However, their involvement in the WT heart is not entirely ruled out, as localization is also 
important and it is unknown if any of these channels are localized to the T-tubule 
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 invaginations.  Staining for CaV1.2, the α1 subunit of cardiac dihydropyridine-sensitive L-
type Ca2+ channels, shows a characteristic striated pattern reflecting their localization in the 
T-tubular system,91 which acts as the basis of calcium-induced calcium release. Staining for 
P2X4 receptors in the P2X4R OE cardiomyocytes demonstrate clusters in the cell periphery 
(Figure 4.1C in the following chapter), thus Ca2+ influx via this channel is unlikely to induce 
spontaneous SR mobilization. Whether other P2X channels are juxtapositioned to calcium 
release units on the SR remains to be studied.  Overall, despite significant membrane 
excitation due to P2X4R activation in the P2X4R OE single cardiomyocytes, we did not 
observe increased propensity for these hearts to be more arrhythmic. Proarrhythmic 
mechanisms active in single myocytes in many cases do not lead to a propagated response 
in the intact tissue, because the current generated by a myocyte will leak away to its 
neighbors without reaching the action potential threshold. The occurrence of a proarrhythmic 
event will have to be synchronized in a sufficiently large group of myocytes in order to reach 
the threshold for propagation away from that area. The transient nature of the P2X induced 
depolarization also makes sustained arrhythmic activity unlikely in the whole heart. 
We initially hypothesized that this transient depolarization due to P2X activation could 
form a basis for the biphasic contractile phenotype seen in the whole heart. That is, a portion 
of cardiomyocytes would initially have arrested APs and attenuated calcium transients that 
reflect the initial depression in the whole heart, which, when followed by a subsequent 
desensitization of the P2X current, would then lead to AP normalization and an enhanced 
calcium transient in the later phase of enhanced contractions. Complementary to altering 
agonist concentration, we hypothesized that increased myocyte surface P2X4R expression 
would augment initial conductance and possibly prolong desensitization kinetics, leading to 
an exaggerated biphasic response at a given concentration of agonist in the P2X4R OE 
animals and ultimately to a left-shifted dose response curve as compared to WT. Our data, 
however, did not indicate an obvious difference between WT and P2X4R OE hearts in terms 
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 of left ventricular pressure development in response to 2-meSATP. A biphasic contractile 
response was observed in both, suggesting that depolarization at the cellular level is not 
essential to the initial depressive phase of 2-meSATP induced biphasic response, as no 
significant depolarization was seen in the WT cardiomyocytes.  2-meSATP, with the 
hydrogen in position 2 of ATP replaced with a methylthio group, is thought to be more 
resistant to nucleotidase breakdown and to lack coronary vasodilatory effects (adenosine 
effect),50 however, some evidence suggest it is also prone to degradation by 
ectonucleotidase enzymes.92 In the whole heart setting, the activity of these enzymes are 
better preserved than in the isolated myocytes preparations, and thus the specificity of 2-
meSATP for P2X receptors in the whole heart is less clear and may explain the lack of 
significant difference between WT and P2X4R OE heart. A small but significant difference 
was observed between WT and P2X4R OE hearts at 1µM 2-meSATP, but additional study in 
a global P2X4R KO line showed a response similar to WT. The persistence of the biphasic 
response in the knockout animals further suggests that this response was not P2X4R specific.  
The biphasic cardiac contractile response to purinergic agonism has been observed 
in a few studies,39, 93, 94 however, this is the first observation in a working mouse heart model 
looking at ventricular function with 2-meSATP as the agonist. The eventual enhancement of 
cardiac function is consistent with previous observations,39, 49, 82 though the mechanism by 
which this is achieved is still debated. It is encouraging that the biphasic contractile response 
has previously been demonstrated in human atrial muscle strips,39 suggesting that the 
cardiac functional responses of P2 agonism may be similar between rodents and human, 
and that it is mediated directly by affecting force generating cells rather than indirectly 
impacting other hemodynamic parameters such as HR. We did observe that with 100µM of 
2-meSATP the heart rate progressively slowed down. This slowing could be a sign of agonist 
breakdown and stimulation of adenosine receptors and/or other Gi coupled P2Y receptors, 
as previous studies have indicated that ATP-induced slowed sinus pacemaker activity can 
60 
 
 be blocked by theophylline and pertussis toxin.95 Similar to previous work, in some cases an 
initial HR acceleration was seen before it slowed, which could be related to release of 
prostaglandins with purinergic activation.95, 96 The existence of multiple subtypes of P2 
receptors in the native heart and additional release of soluble factors complicate 
interpretation, but the crosstalks involved in these signaling pathways may be advantageous 
as P2 agonist-induced positive inotropic effect did not entail a rate related increase in 
myocardial oxygen consumption, as many current inotropes do. 
The decrease in heart rate at the highest concentrations of 2-meSATP can partially 
contribute to the higher pressure development. We also cannot rule out involvement of the 
Frank-Starling mechanism in the later phase of the biphasic response. In the Frank-Starling 
phenomena, stretched muscle fibers can generate larger forces, as it is thought that 
stretching optimizes the overlap and interaction of myosin and actin filaments, and possibly 
also increases the sensitivity of the myofilaments to Ca2+, which further augments force 
development.97 In our experiment, the initial drop in pressure development can lead to 
incomplete chamber emptying and a backlog of volume that accumulates in the ventricle 
during diastole (bulging of the left atrium was sometimes visibly noticeable). This can 
increase stretch on the myofibers and via the Frank-Starling mechanism induce greater 
stroke volume on subsequent contractions. This, however, is unlikely the sole mechanism 
involved as the enhancement can be sustained. While the interpretation of contractile 
response in the whole heart is complicated by a number of considerations and not P2X4R 
specific, we demonstrate that P2X4R induced cardiomyocyte depolarization is transient and 
unlikely increases propensity for arrhythmia development.  
61 
 
 Chapter 4 
P2X4 receptor-eNOS pathway in cardiac myocytes 
as a novel protective mechanism in heart failured 
 
4.1 INTRODUCTION 
  In previous experiments we have demonstrated that mice with P2X4R overexpression 
are protected from heart failure progression in surgically induced and genetically altered 
disease models. While an acute inotropic increase due to P2X activation can be explained 
by its electrophysiological effects, other changes potentially responsible for more chronic 
modulation of cardiac function are unknown. Since the P2X4R is calcium permeable and can 
alter calcium handling inside a cell, a multitude of downstream effects could ensue. One such 
possibility is the interaction with calcium-dependent nitric oxide synthases (NOS). P2X4R 
mediated endothelial nitric oxide synthase (eNOS) activation has been shown previously in 
endothelial cells, 56 with P2X4R deficient P2X4R-/- mice exhibiting aberrant endothelial cell flow 
responses due to a blunting of flow mediated influx of Ca2+ and subsequent production of nitric 
d This chapter has been adapted from two publications: 
1.  Yang T, Shen JB, Yang R, Redden J, Dodge-Kafka K, Grady J, Jacobson KA, Liang BT. "A Novel 
Protective Role of Endogenous Cardiac Myocyte P2X4 Receptors in Heart Failure." Circ Heart 
Fail.  03/2013. 
2. Yang R, Beqiri D, Shen JB, Redden JM, Dodge-Kafka K, Jacobson KA, Liang BT. “P2X4 receptor-
eNOS signaling pathway in cardiac myocytes as a novel protective mechanism in heart 
failure.” Comput Struct Biotechnol J. 13:1-7. 11/2014; Review. 
R.Y. performed immunoblotting, immunostaining, cGMP and S-nitrosylation measurements, and 
some NO imaging experiments.  Dr. Shen and Dardan Beqiri also contributed significantly to NO dye 
imaging. Drs. Redden and Dodge-Kafka provided the Co-IP data. Long-term characterizations of 
animal function after injury involved many other members of the Liang lab. Dr. Tiehong Yang 
performed most ex vivo characterizations, and we also thank Carol McGuiness for care of animals 
and echocardiography, Dr. Chunxia Cronin for performing surgeries, and Dr. Ruibo Wang for 
additional technical assistance.  
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 oxide (NO). These deficits were rescued with adenoviral P2X4R gene transfer. Additionally, the 
P2X4R-/- animals were shown to have higher blood pressure and to excrete smaller amounts of 
NO products in their urine when compared to WT mice, and vessel dilation induced by acute 
increases in blood flow was markedly suppressed.56  
  Cardiomyocytes also constitutively express eNOS and neuronal nitric oxide synthase 
(nNOS),98 and regulation of these enzymes have  significant impact on cardiac function.99, 100 
The protective effect of eNOS and its stimulated second messenger, cGMP, against heart 
failure development is widely confirmed.99, 101 We further examined a possible link between the 
P2X4R and eNOS and considered the existence of a physical interaction. To test for functional 
significance, NO and its downstream readouts were assayed and moreover, inhibition of eNOS 
by pharmacology or genetic knockout was carried out in P2X4R OE transgenic mice subjected 
to postinfarction and pressure overload HF.  
   
4.2 MATERIALS AND METHODS 
 4.2.1 Determination of nitric oxide formation 
NO formation inside isolated cardiomyocytes was first measured by real-time imaging 
with diaminofluorescein-FM diacetate (DAF-FM DA, Molecular Probes, Eugene, OR). 
Cardiomyocytes were loaded with 5µM of DAF-FM DA for 30min at 37°C before imaging on a 
confocal microscope (Zeiss LSM510meta). Rod shaped striated myocytes were randomly 
selected. Fluorescence was excited at 488nM and emission was filtered through a 525nm long 
pass filter. Fluorescence intensities were quantified using MetaMorph (Molecular Devices, Inc, 
Sunnyvale, CA). Myocytes were incubated with vehicle normal saline or 2-meSATP and 
fluorescence determined at baseline and at each minute for 10 minutes.  
In addition to time-series imaging with DAF-FM DA, we utilize a newly commercially 
available NO-sensitive fluorescent dye, 2-[4,5-bis[6-(2-ethoxy-2-oxoethoxy)-2-
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 methylquinolin-8-ylamino]methyl]-6-hydroxy-3-oxo-3H-xanthen-9-yl}benzoic acid (FL2E) in 
its copper complex form [Cu2(FL2E)] (Strem Chemicals, Inc., Newburyport, MA), to image 
NO formation in living cardiac myocytes.102-104 The Cu2(FL2E) NO dye was prepared and 
stored according to manufacturer instructions. Before experiments, myocytes were loaded 
with 5 μM Cu2(FL2E) NO dye for 1 h in Tyrode's solution, then plated onto glass bottom 
dishes for epifluorescence imaging with a Nikon Eclipse TE2000-S. Fluorescence was 
captured with a 480/40 excitation filter and a 535/50 emission filter. Given the observation 
that Cu2(FL2E) demonstrates increased fluorescence with light exposure alone, we 
minimized data acquisition to pre- and 10 minutes post treatment, thus limiting view field 
exposure to light. Random 40× fields rich in rod shaped striated myocytes were selected 
and recorded with a CCD camera. Myocytes were incubated with buffer vehicle or 10 μM 
2-meSATP (Sigma). 100 μM S-nitroso-N-acetyl-D,L-penicillamine (SNAP, Molecular Probes, 
Life Technologies, Grand Island, NY), a NO donor, was used as a positive control. Fluorescence 
intensities from individual rod shaped myocytes were quantified using ImageJ (NIH). Twenty to 
sixty myocytes were counted from each plate before and after treatment for each mouse. 
 
4.2.2 Immunoprecipitation, Immunoblotting, and Immunostaining 
  To test whether there is a physical interaction between P2X4R and eNOS, we 
performed co-immunoprecipitation on cardiomyocyte lysates using mouse monoclonal eNOS 
(BD Transduction; 1-3 µg) and rabbit polyclonal P2X4R (Alomone; 2µg). Cells were lysed in 
HSE buffer (20mM HEPES, 150mM NaCl, 5mM EDTA, 1% Triton X-100 and protease 
inhibitors (leupeptin, pepstatin, benzamidine and ARBSF), pH 7.4). Supernatants were 
incubated at 4°C overnight with the indicated antibody and 15µL of prewashed Protein A/G- 
agarose. Following extensive washing, captured proteins were solubilized in sample buffer and 
analyzed by immunoblot. 
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   For immunostaining of isolated cardiac myocytes to evaluate co-localization of P2X4R 
and eNOS, cardiomyocytes were fixed with 4% paraformaldehyde in PBS for 20 minutes. Cells 
were then cytospun onto slides for staining. Cardiomyocytes were permeabilized with 0.5% 
Triton, and then blocked with 10% normal goat serum plus 3% BSA in PBS for 1 hour at room 
temperature or 4°C overnight. Primary antibodies to eNOS and P2X4R (same as used in co-
immunoprecipitation) were applied both at 1:150 dilution for 1 hour, followed by incubation with 
secondary antibodies (goat-anti-mouse-FITC from Santa Cruz and goat-anti-rabbit-Texas Red 
from Invitrogen) at 1:500 for 45 minutes at room temperature. Confocal fluorescence images 
were acquired on a Carl Zeiss LSM 780 with 488nm and 561nm laser excitation using a 63X oil 
lens (Carl Zeiss Microscopy, LLC, Thornwood, NY). 
  Antibodies specific for eNOS phosphorylation sites Ser1177 (Cell Signaling #9571) and 
Thr495 (Cell Signaling #9574 and Millipore #04-811) were used to assess eNOS activation in 
WT and P2X4R overexpression heart homogenates.  Antibodies from Cell Signaling against all 
three NOS isoforms: eNOS (#9572), nNOS (#4236), and inducible NOS (#2982) were also 
used to examine expression differences.  
 
4.2.3 Determination of cGMP levels 
  NO can lead to soluble guanylate cyclase production of cyclic guanosine 
monophosphate (cGMP). We measured cGMP levels in left ventricular homogenates of P2X4R 
OE and WT animals, following the manufacturer’s acetylated protocol (cGMP determination kit, 
GE Healthcare).  Isolated hearts were perfused with buffer, NO donor S-nitroso-N-
acetylpenicillamine (SNAP, 100µM), or 2-meSATP (10µM) for 10 minutes in the working heart 
mode before they were flash frozen in liquid nitrogen and stored at -80°C for further processing.  
 
4.2.4 Biotin Switch for S-nitrosylated Proteins 
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   Heart tissues were obtained from P2X4R OE and WT animals (n=5 per group). 8 µm 
thick tissue sections were subjected to biotin switch staining following the manufacturer’s 
protocol (S-Nitrosylated Protein Detection Kit, Cayman Chemicals, Ann Arbor, MI). The biotin 
switch method is based on the conversion of nitrosylated cysteines to biotinylated cysteines to 
allow for detection of the NO-mediated modification of cysteine residues (addition of a 
nitrosothiol). Slides were visualized on a confocal microscope (Zeiss LSM 510 meta) at 20X 
magnification. Five 12-bit images of non-overlapping, tissue rich regions were acquired for each 
slide. Images were segmented for positive staining areas, which were summed across five 
images to produce a total area for each slide.  
 
4.2.5   Surgical Models of Heart Failure 
Animals with similar age (8-10 week old) and body weights were used. Mice were 
anesthetized with ketamine (100mg/kg) and xylazine (10mg/kg) intraperitoneally. After 
endotracheal intubation under a dissecting microscope at 37°C, the cannula was connected to 
a small rodent ventilator (Hugo Sachs-Harvard Apparatus, Minivent Type 845, Holliston, MA) on 
room air with a stroke volume of 0.3mL at a rate of 150 per minute. All animal procedures were 
performed according to protocols approved by the University of Connecticut School of Medicine 
Animal Use and Care Committee. 
 
4.2.5.1 Left Anterior Descending (LAD) Ligation as a model of Myocardial Infarction 
 Permanent LAD ligation was performed to induce myocardial infarction (MI) related 
heart failure as previously described.1 After anesthesia and intubation, a left intercostals 
thoracotomy was performed. MI was produced by ligating the LAD with an 8-0 nylon suture 
within 2mm below the edge of the left atrium, near the origin of the coronary artery. 
Echocardiography was performed at 7 and 30 days after ligation to examine heart function in 
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 vivo. Cardiac function was also assessed ex vivo at 30 days after ligation, using the working 
heart preparation (detailed in Section 3.2.4), in which equal loading conditions provide a 
controlled environment to compare contractile performance, complementing 
echocardiography measures.  
 
4.2.5.2 Transverse aortic Constriction (TAC) as a model of Pressure Overload Heart 
Failure 
  This model is distinct from ischemic injury leading to cardiac tissue death, but 
represents a state of chronic afterload which the heart must work harder against to deliver 
sufficient blood. The same opening steps as described above are followed. After left 
intercostals thoracotomy, the thymus was carefully separated to expose the aortic issues 
below it and surrounding tissues were carefully dissected to expose the aortic arch. TAC 
was created by placing a 27-gauge needle on the transverse aorta between innominate and 
left carotid arteries. A ligature of 7-0 Ethilon nylon suture was tied around the needle and the 
aorta, after which the needle was removed. The increase in pressure proximal to the 
constriction was confirmed by an increased Doppler jet velocity across the aortic banding 
site. After euthanasia, the integrity of the banding was confirmed by inspection of the 
surgical constriction and by visualization of differences in the caliber of the right and left 
carotid arteries. All groups of mice had similar pressure gradients across their aortic band. 
Echocardiography was performed at 7 days and 3 weeks after TAC.  
 
4.2.6 Ablating eNOS activity in WT and P2X4R OE animals  
The NOS inhibitor L-N5-(1-iminoethyl)ornithine hydrochloride (L-NIO; Sigma-Aldrich) 
was administered via intraperitoneal injection at 40 mg/kg per day105 beginning at 3 days 
before LAD or TAC until cardiac function determination at 7 days post surgery. Phosphate 
buffer saline injections served as vehicle controls. 
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 Mice globally deficient in eNOS (B6.129P2-Nos3tm1Unc/J) were purchased from the 
Jackson Laboratory (Bar Harbor, Maine) and bred with cardiac-specific P2X4R OE animals 
to obtain P2X4R OE/eNOS KO mice. 
 
4.2.7 Statistics 
Statistical differences were mostly assessed by two-tailed Student's t-test. Two-way 
ANOVA was used to test cGMP content differences across genotype and agonist 
treatment. Data presented as mean ± SEM. We considered P values less than 0.05 to 
be statistically significant.   
 
4. 3  RESULTS 
 
4.3.1 P2X4R can induce NO formation and associates with eNOS  
Since the P2X4R 
receptor is calcium permeant, it 
is possible that this receptor can 
interact with and activate the 
calcium-dependent endothelial 
nitric oxide synthase (eNOS). 
We investigated whether 
stimulation of P2X receptors in 
cardiac myocytes can lead to 
formation of nitric oxide 
molecules. Using the traditional 
4-amino-5-methylamino-2’,7’-
difluorofluorescein (DAF-FM) diacetate dye for imaging nitric oxide (NO) in P2X4R OE 
Figure 4.1  Example of change in DAF-FM 
intensity at baseline vs. after exposure to P2X 
agonist or vehicle. Note the declined intensity in 
vehicle-treated cells due to photobleaching of 
fluorescein. Bars indicate 10µm. 
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 cardiomyocytes, increased fluorescence was observed over baseline or vehicle-treatment 
following 2-meSATP treatment (Figure 4.1). After 10 minutes, mean intensity with agonist 
normalized to those with vehicle was 109.3±2.6% (n=33 cells for vehicle-treatment and n=43 
cells for 2-meSATP, P<0.05). As evident from vehicle treatment, DAF-FM has the drawback 
of photobleaching. Thus we repeated NO formation measurements with a newer NO-
sensitive fluorescent dye, Cu2(FL2E), which has been used to image NO formation in a  
 
 
Figure 4.2   2-meSATP stimulated NO formation in P2X4R OE and WT cardiac 
myocytes imaged with Cu2(FL2E) (a) Upper panel: Representative fluorescence 
images of Cu2(FL2E) loaded P2X4R OE cardiac ventricular myocytes before and after 
SNAP or 2-meSATP treatment are shown. Lower figure: Quantification of 
fluorescence change normalized to pre-treatment, *P<0.05 using paired t-test for 
average fluorescence intensity before and after treatment with SNAP (n=4 mice) or 2-
meSATP (n = 3 mice) from P2X4R OE animals. (b) Similar studies were carried out in 
cardiac ventricular myocytes from WT animals (n = 2 mice). Upper and lower panels 
show typical fluorescence imaging and average fluorescence intensity for treatment with 
SNAP and with 2-meSATP. *P<0.05 using paired t-test for SNAP or 2-meSATP 
treatment. 20-80 cells were counted from each mouse for each treatment condition. Bars 
indicate 10µm.  
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 variety of biological systems, including intact living cardiomyocytes. Cu2(FL2E) data 
confirmed NO formation following 2-meSATP stimulation in P2X4R OE myocytes (Figure 
4.2a), as well as in WT myocytes (Figure 4.2b), with the former exhibiting greater NO 
formation. Thus, using two structurally distinct dyes specific for NO, we demonstrate that 
NO is increased within cardiac myocytes as a result of P2X receptor stimulation in both 
P2X4R OE transgenic myocytes and WT cardiac myocytes. 
In considering a mechanism for NO production following P2X4R stimulation, the P2X4 
receptor was found to be present in eNOS immunoprecipitates obtained from cardiac 
myocytes of both WT (Figure 4.3a) and P2X4R OE (Figure 4.3b) hearts. The specificity of 
this physical interaction was supported by the absence of P2X4R in immunocomplexes 
captured using an IgG matched control antibody. P2X4R and eNOS were both more 
concentrated in sarcolemmal regions as assessed by immunostaining, and appear in close 
proximity in specific areas along the sarcolemma (Figure 4.3c). Both proteins also showed 
sarcolemmal staining in WT myocytes, although P2X4R staining was considerably fainter. The 
increased NO production in P2X4R OE hearts was not due to an up-regulation of eNOS 
protein expression or increased catalytic activity via phosphorylation of the serine 1177 
residue (Figure 4.3d). There was no discernible band on immunoblots of WT and P2X4R OE 
heart homogenates for phospho-eNOS Thr495, nor for iNOS. No difference was seen in 
nNOS expression between the two genotypes (blot not shown). These data support the 
activation of eNOS to produce NO following P2X4 channel activation. 
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Figure 4.3  P2X4R and eNOS are co-immunoprecipitated and can exist in close 
proximity in cardiac ventricular myocytes (a) WT myocyte lysates were incubated 
with anti-eNOS antibody or with non-specific IgG as control. The isolated complex was 
probed with eNOS (top panel) and P2X4R (bottom panel) antibodies. P2X4R co-
immunoprecipitated with eNOS antibody (lane 3) but not with control IgG (lane 2) and 
self-precipitation by eNOS also served as a control. (b) Same experiment as in (a) 
conducted in P2X4R OE transgenic myocytes. (c) Immunostaining of eNOS (green), 
P2X4R (red), with merged image shown for a P2X4R OE cardiac myocyte. Bar 
indicates 10µm. (d) Protein expression of eNOS did not differ between P2X4R OE and WT 
hearts and neither did phosphorylation of Serine 1177 (p-S1177) on eNOS. Blots are shown 
on the left and lane quantifications shown on the right (n = 5 each, P=0.32 for comparison of 
eNOS expression as normalized to GAPDH, and P=0.66 for p-S1177 as normalized to 
eNOS). 
    d 
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 4.3.2   P2X4R stimulated NO formation leads to downstream signaling 
NO can induce further downstream signaling activity, likely through stimulation of 
soluble guanylyl cyclase activation and 3′,5′-cyclic GMP (cGMP) formation, as well as 
through the more recently discovered S-nitrosylation of cellular proteins. Indeed there was 
an increased level of myocardial S-nitrosylation in P2X4R OE hearts as compared to WT 
hearts (Figure 4.4a), in agreement with enhanced endogenous NO production. To assay 
potential changes in cGMP, isolated hearts were perfused with buffer, 10µM 2-meSATP, or 
100µM NO donor SNAP. SNAP caused a large increase in cGMP levels (buffer-perfused 
P2X4R OE: 2.61±0.33 fmol/mg, n=5 vs. SNAP-perfused P2X4R OE: 5.61±0.40 fmol/mg, n=5, 
P<0.05). The cGMP level was also higher in P2X4R OE hearts than in WT hearts after 2-
meSATP treatment, with similar drug responses in both genotypes (WT+buffer: 2.36±0.21 
fmol/mg, n= 15;  WT+2-meSATP: 2.83±0.26 fmol/mg, n=12; P2X4R OE+buffer: 
2.76±0.19 fmol/mg, n=18; P2X4R OE+2-meSATP: 3.39±0.20 fmol/mg, n=16; two- 
way ANOVA p<0.05 for both P2X4R OE and 10µM 2-meSATP treatment with no 
 
Figure 4.4 Increased cardiac protein S-nitrosylation and cGMP content in P2X4R OE 
animals. (A) Typical examples of S-nitrosylated proteins in P2X4R OE and WT hearts (n = 5 
for each) as determined using the biotin switch method. Bar indicates 30µm. Summed 
positive areas from 5 images per heart produced one total area for each heart, with P2X4R 
OE hearts showing a significantly greater area of positive staining compared to WT 
(58563±9603 pixels for P2X4R OE vs. 31589±3771 pixels for WT, P=0.03). (B) Cardiac 
tissue cGMP content is overall significantly higher in P2X4R OE hearts vs. WT and in hearts 
that have been perfused with 10µM 2-meSATP vs. buffer (n= 15 for WT + buffer, n=12 for 
WT + 2-meSATP, n=18 for P2X4R OE + buffer, and n=16 for P2X4R OE+ 2-meSATP).  
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 significant interaction, summarized in Figure 4.4B). These data are consistent with 
stimulation of the overexpressed cardiac P2X4R by endogenous extracellular ATP leading 
to S-nitrosylation of proteins and cGMP formation in P2X4R OE hearts. Overall, 
multiple lines of evidence point to P2X4 receptor-induced intra-myocyte NO production 
with downstream functional consequences. 
 
4.3.3 Cardiac P2X4R OE improved function after Pressure Overload  
 In addition to the previously demonstrated salutary effect of P2X4R OE against 
ischemia cardiac injury, P2X4R OE mice were also protected against pressure overload 
induced HF. The differences between P2X4R OE and WT manifested early. As early as 7 
days after TAC, echocardiographic assessment demonstrated a significant difference 
between WT and P2X4R OE mice, and better preserved function in P2X4R OE mice 
continued to be evident at 3 weeks (Figure 4.5). 3 weeks after TAC, we observed moderate 
left ventricular hypertrophy with reduced cardiac fractional shortening in most animals but no 
overt HF or arrhythmias. P2X4R OE hearts also showed less fibrosis than WT hearts (n=16 
for P2X4R OE, n=11 for WT, P<0.05 with both Picrosirius Red and Trichrome staining).   
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Figure 4.5 P2X4R OE hearts have better cardiac function after transverse aortic 
constriction. (A) P2X4R transgenic (Tg) mice (n=12) had better preserved fractional 
shortening (FS) and greater ejection as marked by smaller left ventricular internal 
diameter at end systole (LVIDs) compared to WT (n=11) at 7 days after TAC. (B) 
Echocardiographic parameters again demonstrated higher FS and smaller LVIDs in 
P2X4R Tg (n=16) than WT (n=18) 3 weeks after TAC. (C) Examining heart function ex 
vivo showed greater +dP/dt and –dP/dt in Tg (n=18) than WT (n=18) hearts. γ P<0.05 
P2X4R Tg vs. WT after 7 days of aortic banding; *P<0.05 WT subjected to TAC was lower 
vs. sham WT (n=8), sham Tg (n=8 and 9) or Tg subjected to TAC; ** P<0.05 Tg subjected 
to TAC was different from sham Tg or sham WT. 
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 4.3.4 Role of eNOS in mediating the protective effect of P2X4R in Heart Failure 
In order to examine the role of eNOS in mediating P2X4R protection, we used a 
pharmacological inhibitor of NOS, L-NIO, as well as gene ablation of eNOS in P2X4R OE 
mice during heart failure (summarized in Figure 4.6). In one set of studies, we used the 
ischemic heart failure model involving permanent ligation of the LAD coronary artery to 
cause post-infarct heart failure. P2X4R OE led to a higher cardiac left ventricular fractional 
shortening (FS) after infarction, but no infarct size difference was observed in mice of 
various genotypes that were subjected to the ligation. Daily injection with L-NIO, which 
has been used to demonstrate eNOS function in vivo,105 abrogated the improved 
cardiac performance of P2X4R OE mice during ischemic HF when compared to WT, 
as determined by both in vivo echocardiography and by ex vivo working heart 
examination. 
To further confirm the role of eNOS in mediating the protective effect of the P2X4R 
during HF, eNOS KO mice were crossed with P2X4R OE mice (P2X4R OE/eNOS KO). 
KO of eNOS abrogated the protected phenotype conferred by the P2X4R OE genotype 
in postinfarction HF. Both the improved + dP/dt and FS in P2X4R OE mice during HF were 
lost in P2X4R OE/eNOS KO mice. To ascertain whether the protective effect of P2X4R–
eNOS is applicable to another form of HF, we tested the effects of P2X4R-induced protection 
by pharmacological inhibition of eNOS on pressure overload HF. Pressure overload was 
produced by aortic banding in P2X4R OE and WT mice. P2X4R OE hearts showed better 
cardiac function as determined by echocardiography- derived FS after aortic banding. L- 
NIO blocked the increased FS in these animals. KO of eNOS in Tg animals also 
abrogated the improved FS in these Tg mice after aortic banding. These data provide 
functional evidence for a P2X4R–eNOS interaction and support a key role of eNOS as a 
mediator of cardiac P2X4R-induced protection in HF. 
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Figure 4.6 eNOS activity inhibition abrogated the improved cardiac function by P2X4R overexpression in heart failure.  
(A) Daily injection of L-NIO 3 days before and 7 days after LAD coronary artery ligation in P2X4R OE transgenic (Tg) mice (n=13) 
resulted in a reduced FS compared with P2X4R OE mice not receiving drug (n=24). P2X4R OE mice receiving L-NIO had similar FS 
as WT receiving the drug (n=21). (B) KO of eNOS in P2X4R OE mice blocked the improved +dP/dt and (C) FS by P2X4R 
overexpression in postinfarct heart failure thirty days after LAD ligation. P2X4R OE mice (n=20) showed better +dP/dt compared with 
P2X4R OE/eNOS KO (n=22), WT (n=9), or eNOS KO mice (n=21). Similarly, P2X4R OE mice (n=9) had greater FS than any other 
genotype at 30d after ligation. WT (n=10), eNOS KO (n=14), P2X4R Tg/eNOS KO mice (n=12) did not differ in FS (ANOVA and post-
test comparison). 3 weeks after TAC, (D) P2X4R Tg mice treated with vehicle subjected to TAC (n=22) had higher FS compared with 
Tg animals that had received L-NIO injections (n=11); WT (n=11) and P2X4R Tg mice treated with L-NIO had similar FS. (E) P2X4R 
OE mice (n=8) showed better FS compared with P2X4R Tg/eNOS KO (n=12) or eNOS KO mice (n=13). *P<0.05 vs any other group 
on the same graph. P>0.05 among groups not marked. 
 
 
 4.4 DISCUSSION 
In adult murine ventricular myocytes, the P2X agonist 2-meSATP induced a nonselective 
cation current with reversal potential similar to that of the cloned P2X4 receptor.47 Transgenic 
mice with cardiac-specific overexpression of the human P2X4R have previously been shown to 
be protected from ischemic HF induced by LAD ligation and from a genetic model of dilated 
cardiomyopathy from the overexpression of calsequestrin.1, 52 Previous evidence suggested that 
activation of cardiac P2X receptors can elicit a cyclic AMP-independent increase in cardiac 
contraction106 and as we discussed in the previous chapters, an electrophysiological basis exists 
for increasing myocardial calcium transients and contraction.47, 107 However, the mechanisms by 
which these ligand-gated channels protect against HF remain incompletely understood. Here we 
demonstrated that eNOS is an effector in P2X4R-mediated cardioprotection.  
Direct measurement of NO production was made in P2X4R OE and WT cardiac myocytes 
after 2-meSATP stimulation. DAF-FM demonstrated a greater stimulated increase in NO level in 
P2X4R OE over WT myocytes. The newer NO-sensitive dye Cu2(FL2E) corroborated the finding, 
showing enhanced fluorescence in both WT and P2X4R OE cardiac myocytes after treatment 
with the agonist, and a larger magnitude of change in the P2X4R OE myocytes. Furthermore, 
the level of S-nitrosylated proteins and cGMP were higher in transgenic than in WT hearts, 
consistent with a greater stimulation of endogenous NO production by the overexpressed P2X4 
receptors in transgenic hearts. These findings provide functional evidence for the activation of 
eNOS downstream of cardiac P2X4 receptors. The expression of eNOS in cardiac myocytes is 
relatively low,108 but a modest increase in DAF fluorescence by a synthetic nitrone in murine 
cardiac myocytes had a functionally significant impact in reversing contractile dysfunction,109 
and our data showed a similar degree of increase in DAF fluorescence after P2X agonist 
stimulation. The P2X4 receptor coimmunoprecipitated with eNOS in isolated cardiac myocyte 
lysates from both P2X4R OE and WT animals. Co-immunostaining of P2X4R and eNOS in the 
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 sarcolemma of P2X4R OE transgenic cardiac myocytes further supports an interaction of these 
two proteins. In considering other aspects of eNOS activation, phospho-eNOS Ser1177 
normalized by total eNOS expression was unchanged in P2X4R OE vs. WT hearts. 
Phosphorylation of Ser1177 increases eNOS catalytic activity, representing a mechanism of 
eNOS activation different from that achieved by calmodulin binding.110 We postulate that the 
mechanism of eNOS activation by P2X4 receptors is from Ca2+ increase and subsequent 
calmodulin binding and may not involve Ser1177 phosphorylation. A close proximity between 
P2X4 receptor and eNOS may prime for a confined domain of calcium to activate calmodulin 
and subsequently eNOS.  In endothelial cells where eNOS is more abundant, P2X4R has also 
been implicated in stimulating eNOS,56 though the physical interaction between P2X4 receptor 
and eNOS remains unstudied in the endothelium.  
If the interaction of eNOS with cardiac P2X4 receptor is important in mediating the 
protective effect seen in P2X4R OE animals, one would expect that the inhibition of eNOS could 
block the cardiac P2X4 receptor protective effect, and we indeed found this. Either 
pharmacological inhibition of eNOS by L-NIO or genetic KO of eNOS abrogated the HF 
protective effect of cardiac P2X4R OE. Cardiac P2X4R OE ameliorated both ischemic and 
pressure overload forms of HF. The cardioprotective effect of eNOS in ischemia/reperfusion 
injury and in post-infarct HF has been demonstrated in eNOS-overexpressing transgenic 
animals 111-113. Upregulating eNOS by H2S has also been shown to protect against pressure 
overload HF.114 Although eNOS overexpression or upregulation is cardioprotective, eNOS KO 
has been reported to increase, decrease, or cause no change in ischemia/reperfusion injury.111 
The reason for these variable findings may have to do with the presence or absence of a 
compensatory upregulation of inducible NOS in some of the eNOS KO mice. The eNOS-/- line 
used in the present study, developed at the University of North Carolina and now available from 
the Jackson Laboratory, has been shown to have upregulated iNOS.111 We did not observe a 
more severe HF phenotype after infarction in these eNOS knockouts, consistent with their 
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 compensated phenotype. Nonetheless, protection provided by the P2X4R-eNOS interaction in 
the P2X4R OE hearts was abrogated by eNOS knockout.  
Additional caution was exercised when interpreting the data from L-NIO and eNOS KO 
mice. While L-arginine analogues such as L-NIO are believed to be NOS inhibitors, they may 
have other actions that secondarily affect remodeling after pressure overload or infarction as a 
consequence of its inhibition of eNOS in the endothelium, such as inducing hypertension and 
vasoconstriction. The eNOS KO animals exhibit mild hypertension and LV hypertrophy that 
could in turn confound the salutary effect of cardiac myocyte-specific P2X4R OE. A more severe 
HF could potentially result from pressure overload in eNOS KO animals, which may in turn 
abrogate the beneficial effect of cardiac P2X4R OE. However, when the same eNOS KO mice 
as used here were subjected to abdominal aortic banding, they did not show LV dilation when 
compared with WT controls.115 In fact, ejection fraction was greater in eNOS KO than in WT 
mice after abdominal banding. This apparent protection against abdominal banding may be 
because of the compensatory upregulation of iNOS. However, in our postinfarct hearts, eNOS 
KO was not protective because cardiac function was similarly depressed in both eNOS KO and 
WT mice (Figure 4.6B).  
The present data are consistent with previously reported protection by eNOS via the T-
type calcium channel in pressure overload HF.105 Although eNOS is cardioprotective, the 
downstream effectors mediating eNOS activity are not entirely clear. Possible candidates 
include cGMP, protein kinase G, and cellar protein S-nitrosylation.58, 116 Cardiac-specific 
activation of eNOS may be more cardioprotective than an increased activity of global systemic 
eNOS113 and intra-myocyte formation of nitric oxide may be more advantageous over nitric 
oxide derived externally from a donor. Overall, new evidences support a P2X4R-eNOS 
interaction and its functional significance in HF protection, pointing to a novel sarcolemmal 
receptor-enzyme pathway in the heart.  
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 Chapter 5  
 
Conclusionse  
 
 
5.1  SUMMARY OF FINDINGS 
P2X receptors are ligand-gated ion channels that regulate various physiological 
processes and have emerged as promising therapeutic candidates for treatment of several 
pathophysiological conditions such as heart failure. The transition from experimental validation 
to clinical use necessitates a detailed mechanistic understanding of P2X mediated cardiac 
effects, as well as potential side-effects of targeting these receptors. In the studies presented in 
this dissertation, the downstream effects of activating these extracellular ATP responsive 
receptors in cardiac myocytes were examined in a transgenic mouse model with cardiac specific 
overexpression of the P2X4 subtype (P2X4R OE), as compared to wildtype (WT) and other 
animals with relevant genetic modifications. We focused on electrophysiological consequences 
that are of paramount importance to the cardiomyocyte and also uncovered a novel protein 
interaction that has functional implications downstream of altered ion handling. First, in Chapter 
2 we confirmed the hypothesis that cardiac P2X receptors can modulate the cardiac contractile 
state by adjusting Na+ handling. Measurements of Na+-K+ ATPase (Ip) and Na+/Ca2+ exchanger 
(INCX) currents in ventricular myocytes isolated from P2X4R OE mice indicated that the agonist, 
2-methylthio adenosine-5-triphosphate (2-meSATP), increased peak Ip and the Ca2+ entry mode 
of INCX. These results were supported by simulation and showed that 2-meSATP caused an 
estimated [Na+]i increase of around 1mM. Inhibitors that preferentially oppose the Ca2+ entry 
mode of NCX, KB-R7943 or a structurally different agent YM-244769, blunted the 2-meSATP-
induced increase in cell shortening in P2X4R OE myocytes, suggesting that the Ca2+ entry mode 
e Part of this chapter exists in print: Yang R, Liang BT. “Cardiac P2X4 Receptors: Targets in Ischemia and Heart 
Failure?” Circ Res. 111:397-401. 08/2012. 
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 of INCX participates in the P2X agonist-stimulated enhancement in contraction. In ventricular 
myocytes from WT mice, despite a limited responsive subpopulation, P2X agonist also 
increased INCX and KB-R7943 was able to inhibit contractile effects elicited by the agonist. 
These data demonstrate a novel Na+ entry pathway through ligand-gated P2X4R in 
cardiomyocytes that can subsequently modify contractile responses via the NCX.  
In Chapter 3, we described experiments designed to better understand the potential 
balance between arrhythmogenic effects versus anti-ischemic and heart failure protection 
benefits of P2X4 receptor activation. Again utilizing cardiac specific P2X4R OE animals, we 
found that activation of these receptors could lead to a brief period of membrane disturbance 
lasting around half a minute, which can be mimicked with a computational model based on 
known P2X4 current kinetics. This transient excitability of the P2X4R OE cardiomyocytes did not 
translate to enhanced automaticity in the whole heart, and supports the notion of targeting P2X 
subtypes for cardiac inotropic support with transient effects on excitability. Previous conflicting 
results reflect measurements at different time points in the dynamic response and could also 
result from different agonists and doses used in the studies. Low concentrations of P2X agonist 
may be able to elicit an increase in contraction but not induce sufficient depolarization to cause 
ectopic beats and diastolic calcium buildup, which were only observed at >10µM of ATP and 
likely involve mechanisms other than P2X activation. Additionally, we unveiled a previously 
unreported biphasic response to P2 agonism in the mouse heart, which was present in WT and 
P2X4R KO animals as well. This substantiates the existence of multiple subtypes of P2 
receptors in the native heart and emphasizes the importance of understanding the actions of 
specific P2 subtypes.  
Lastly, in Chapter 4 we reported a novel feature of the P2X4R in that the receptor is not 
just an ion channel, but can associate with the enzyme endothelial nitric oxide synthase (eNOS). 
In the cardiac myocyte, we showed that P2X4 receptor stimulation causes activation of eNOS, 
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 as demonstrated by increased NO formation with two structurally distinct NO-sensitive 
fluorescent dyes. Cardiac tissue from P2X4R OE mice also showed enhanced S-  
 
  
Figure 5.1   Model of the mechanism of action of P2X receptors in cardiac 
myocytes Ionic influx due to activation of the P2X4 receptor can lead to intracellular Na+ and 
Ca2+ concentration changes, partly by affecting the NCX. A localized increase in Ca2+ near 
eNOS can increase eNOS activity via calmodulin dependent activation. Some of the 
increase in calcium is taken up by the sarcoplasmic reticulum (SR). NO production can lead to 
stimulation of soluble guanylyl cyclase (sGC) with cyclic GMP accumulation as well as S-
nitrosylation of myocardial proteins. The NO pathway is known to exert a salutary 
effect in heart failure and in ischemic injury. 
 
nitrosylation and cGMP content. Blunting eNOS activity in P2X4R OE animals abrogated the 
protective effect seen in these animals after surgically induced cardiac injury, consistent with a 
functional significance for the P2X4R–eNOS pathway in mediating cardioprotection in heart 
failure.  
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 Overall, we propose the model summarized in Figure 5.1, where Na+ entry via the P2X4 
receptor enables further ion exchange through the NCX to enhance calcium retention inside the 
cell. It is conceivable that P2X4 flux exerts a primarily localized control over calcium mediated 
signaling with minimal or no effect on Ca2+ influx in the dyadic space. Diffusion of Ca2+ ions 
allows them to reach and enter the SR for enhanced loading and inotropic enhancement. The 
close physical distance between the P2X4R and eNOS primes NO production, which is beneficial 
in the setting of ischemic injury and heart failure.  
 
5.2  FUTURE DIRECTIONS 
5.2.1 Additional P2X4R considerations for Regulating Cardiac Function 
In addition to directly modulating cardiomyocyte ion handling in the classical excitation 
contraction paradigm, the P2X4 receptor has been implicated in a number of physiological 
processes that could indirectly modify cardiac function. Another possible mechanism by which 
P2X4R may be of benefit in the diseased heart may lie with its mechanosensitive properties. It is 
structurally similar to members of the mechanosensitive epithelial Na+ channel (ENaC) family, 
and it has been shown that P2X4 receptor desensitization to repeated ATP stimulation is 
prevented by applying shear stress to P2X4 expressing Xenopus oocytes.117 While this open-
channel stabilizing mechanism is conceptually different from that of mechano-induced ATP 
release and subsequent channel activation,56 they both support an important role for P2X4R in 
cellular response to mechanical force. In the remodeling heart experiencing increased 
mechanical stress, it is possible that enhanced P2X4R stimulation/opening may serve to 
enhance cardiac contractility. Detailed examination of P2X4 activation and kinetics in myocytes 
under mechanical loading may be feasible with recently developed techniques.118  Additionally, 
the P2X4R has recently been demonstrated to exist on lysosome-related exocytotic vesicles. 
Fusion of these vesicles to the plasma membrane leads to localized calcium increase that 
further induces Ca2+-dependent vesicular fusion, promoting compound exocytosis.119 While the 
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 molecular exocytotic machinery in the heart is not well understood, it is tempting to speculate 
that enhanced P2X4R signaling in ischemia or heart failure may augment cardiac release of 
vesicular contents, which could contain cytokines and/or cardioprotective factors. Secretion of 
natriuretic pepetides and vascular endothelial growth factor (VEGF) are known to be stimulated 
under a number of conditions that involve hypoxia and mechanical stretch;120, 121 and P2X4R-
mediated release of inflammatory mediators such as the known cardioprotectant brain-derived 
neutrophic factor (BDNF)122 and P2X4R involvement in NLRP1 inflammasome signaling have 
been demonstrated in spinal cord and peripheral nerve injuries.123 These scenarios are also 
pertinent to myocardial injury, in which inflammatory responses are necessary for tissue repair 
but need to be controlled and weighed against compensatory mechanisms to improve cardiac 
function. The P2X4R receptor may be a novel participant in the regulation of this process.  
 In response to peripheral inflammatory challenges, mice lacking the P2X4R show a 
complete absence of inflammatory prostaglandin E2 (PGE2) in tissue exudates and 
consequently do not develop pain hypersensitivity due to the lack of PGE2 promotion of sensory 
neuron hyperexcitability. PGE2 synthesis involves the activation of a multi-step enzymatic 
cascade that includes cyclooxygenases (COXs), the targets of nonsteroidal anti-inflammatory 
drugs. COX-2 inhibitors are used as anti-inflammatory and pain medication worldwide, though 
they have been associated with elevated cardiovascular risk.124, 125  While a P2X4R antagonist 
may be useful as a new therapy to treat neuropathic pain,126 our current data suggest that its 
antagonism may be deleterious to those individuals under cardiac stress as well, including heart 
failure. Modulating inflammatory responses has been considered a potential therapeutic 
approach to preserve and recover heart function after myocardial infarction as well,127, 128 and 
the role of the P2X4R in this setting remains to be clarified.  A number of mouse models with cell 
type specific knockout of the P2X4R are currently under development in our lab to permit 
determination of the function of each component (cardiac myocytes, endothelial cells, and 
monocytes) without confounding influence from other tissues and will together serve to 
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 illuminate a better systemic view of targeting this receptor in cardiac treatment. Recent data on 
cardiac specific P2X4R knockouts showed worse outcome after ischemic and pressure overload 
injuries,129 consistently with myocyte P2X4 receptors being cardioprotective in disease.  
 
5.2.2 Understanding Human Polymorphisms in P2X receptors 
Genetic variants in the human population can be quite informative about the 
mechanisms of disease. In two Australian cohorts of healthy human subjects, containing 430 
and 2874 subjects, a common allele with a non-synonymous single nucleotide (Tyr315 Cys) 
polymorphic variant of the P2X4R gene was found to occur at a frequency of 1.1 and 1.4% 
respectively. This loss-of-function genetic variant in humans is associated with increased blood 
pulse pressure,57 consistent with the role of P2X4R in regulating vascular tone.56, 130  It has also 
been found, along with another polymorphism in the P2X7R gene, to form a haplotype that 
increases the risk of age-related macular degeneration in a cohort of 744 patients vs. 557 
controls, likely due to impaired monocyte phagocytosis.131 These observations are consistent 
with important roles for the P2X4R in processes that could impact cardiac function and 
remodeling after injury and it would be of interest to test if this variant occurs with a higher 
prevalence in heart failure. Complementary to the tissue specific knockout models, global and 
tissue specific knockins of this polymorphic variant can serve as more relevant study models for 
human disease.  
 
5.2.3 Calcium and Nitrosative Signaling in Heart Failure 
Electrophysiological remodeling in HF is complex and evolves over time as HF 
progresses. In the early stages of HF, Ca2+ transients can be increased, likely due to elevated 
intracellular Na+ concentration and relatively normal SR function at this time point.132 In the late 
stages of HF, SERCA down-regulation and RyR leakiness depress SR storage, and along with 
modifications of sarcolemmal channels and T-tubule disruption, contribute to dyssynchronous 
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 calcium release and impaired contraction.133 The cause and sequence of these changes remain 
mostly unclear. Oxidative and nitrosative balance is also disturbed in heart failure. In healthy 
tissue, superoxide is produced by xanthine oxidase, mitochondria, and NADPH oxidase, and 
becomes rapidly buffered by glutathione and broken down by superoxide dismutase.109 The 
diseased myocardium has elevated superoxide levels, along with a nitroso-redox imbalance, can 
alter the function of a variety of excitation-contraction coupling proteins leading to contractile 
dysfunction.133, 134  Dysfunctional NOS activity has been shown to lead to hyponitrosylation of the 
RyR receptor, contributing to SR calcium leak and enhanced xanthine oxidase activity.135, 136 
Antioxidant treatments have been shown to increase contractile function and promote 
cardioprotection in failing hearts,137, 138 with success possibly incumbent on NO bioavailability.139 
Therapies aimed at increasing endogenous NO bioavailability may also be beneficial.140  Whether 
P2X dependent enhancement in contraction and NO production can function with significant late 
alterations in the failing cardiomyocyte remain to be examined, as timing of therapy will likely 
impact outcome. Early intervention may be necessary to observe optimal P2X4-mediated 
protection. 
 
5.2.4 Developing pharmacological tools and therapeutic drugs 
In addition to P2X-mediated contractile enhancement and cardioprotection, recent 
studies have also suggested differential roles played by various P2 receptors. P2Y11 receptors 
may be largely responsible for ATP-induced inotropic increase, acting through cAMP and PLC 
dependent pathways.89 The P2Y2 receptor has been suggested to mediate UTP-conferred 
protection against myocardial damage after myocardial infarct,141 though the existence of this 
receptor at the protein level has not been confirmed in the human heart.41 In P2Y2 knockout 
mice, the UTP-conferred reduction in infarct size and improvement in cardiac function were 
abrogated.141 Additional evidence supports stimulation of P2Y2 receptors as a protective 
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 mechanism to decrease angiotensin type 1 receptor density in cardiac fibroblasts through 
inducible NOS-mediated S-nitrosylation of the p65 subunit of NF-kB, thus negatively regulating 
angiotensin II-mediated inflammatory responses in the heart.142  The P2X7 receptor has also 
been implicated in mediating effects of ischemic preconditioning and postconditioning, by 
interacting with pannexin-I hemichannels to release multiple cardioprotectants in Landendorff ex 
vivo rat hearts,143 which could be interesting given the functional haplotype with P2X4R. 
However, another study exposing HL-1 atrial cells to hypoxic stress in culture detected an early 
rise in ATP in culture, followed by increased release of cytoplasmic histone-associated DNA-
fragments, indicating cell death that was thought to be directly induced by P2Y2 and P2X7 
receptor subtypes, whereas the P2Y4 receptor was thought to exert a protective effect.144 
Addition of apyrase to degrade extracellular ATP, or adding GAP26 or 18aGA to inhibit 
connexin hemichannels, also abolished hypoxic stress-associated apoptosis.144 The implications 
of these results warrant further characterization and studies across different model systems. 
Understanding the physiological roles of individual P2 receptors in the heart will be imperative 
as interest grows in targeting purinergic receptor signaling in treating heart failure and ischemia. 
The many permutations of subtype combinations and the paucity of highly selective agonists 
and antagonists have made it difficult to ascertain the specific role of each P2 receptor in the 
heart. Additional pharmacological tools, accompanied by genetic modifications and our 
increasing ability to differentiate cells into specific lineages, may prove efficient at elucidating 
cell type-specific molecular and cellular mechanisms.  
Coronary heart disease and myocardial infarction are disorders of high prevalence and 
incidence. According to the American Heart Association, a heart attack occurs every 34 
seconds. Our results indicate that a small molecule drug stimulating or gene therapy-mediated 
overexpression of the P2X4R in cardiac myocytes may represent a new therapy for both 
ischemic and pressure overloaded HF. In light of the recent crystal structure obtained from 
zebrafish P2X4R in the open state with ATP binding,145 new information on the conformational 
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 changes associated with P2X channel gating will enable guided design of new pharmacological 
agents. Crystal structure and site-specific mutagenesis of P2X4R have elucidated the ATP-
binding pocket, which resides at each pair of subunit interfaces in the trimeric channel. Four 
positively charged lysine and arginine residues line the binding pocket for ATP, whose 
phosphate groups mediate ligand specificity (ATP>ADP, AMP). Lys70 and Thr189 (Lys67 and 
Thr186 in human homologue) are important in maintaining specificity over CTP, GTP, and 
UTP.145 The human Tyr315Cys mutation that disrupts agonist binding is located within this 
pocket. Additionally, the open state of the receptor leaves relatively large gaps that could be 
filled in by lipids and allosteric modulators such as ivermectin.145 Detailed mechanisms of how 
the open state can be stabilized by such modulators, and more intriguingly by mechanical 
forces,117 would be of interest in future investigations. Additional challenges in drug design 
include rapid adenine nucleotide degradation by extracellular nucleotidases and the negative 
charges on nucleotides preventing oral absorption. Development of nucleotidase-resistant 
ligands146 and prodrugs at P2X4 receptors with masked charges that can be restored after oral 
absorption are additional goals for clinical application. 
 
5.2.5 Computational Modeling of the Cardiac System 
Quantitative modeling has served to enhance our understanding of AP generation and 
excitation contraction coupling for more than half a century, reaching an advanced level allowing 
accurate predictions for experimental studies. In our case, simulation results prompted studies 
that helped to explain prior experimental disagreements and confirmed the notion that P2X 
activation can achieve inotropic enhancement. While some improvements can be made to 
incorporate more detailed descriptions of cardiac ion channels and proteins involved in EC 
coupling, such as incorporating Markovian models of the Na+/K+ ATPase147 and SERCA148, 
more interesting areas for future modeling investigations will involve channel modulation by cell 
signaling pathways. Beta-adrenergic receptor and calcium/calmodulin-dependent protein kinase 
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 type II signaling pathway models in the heart have been under development,132, 149, 150 and nitric 
oxide signaling would be another area of major interest. Models of myocardial energetics are 
also being pursued,151, 152 which would serve as a crucial link to understand mismatched energy 
supply and demand in heart failure and to understand the interactions between metabolism and 
intracellular redox and nitrosative regulations.153 The actions of signaling proteins on their 
molecular targets and the dynamics of the signaling pathway need to be incorporated, along 
with spatial considerations and information transfer between organelles, for a holistic 
understanding of the cellular system’s interactions. While significant challenges will need to be 
overcome, tissue and organ level models are also useful for understanding AP propagation and 
structure-related functional changes that occur in myocardial injury and failure, and may be 
potentially useful in the clinical environment as tools to aid in the prevention, diagnosis and 
treatment of cardiac diseases.154  
 
5.3 FINAL THOUGHTS  
This dissertation characterized the effects downstream of P2X4R activation in the 
cardiomyocyte, and our results have pointed to a potentially rewarding translational outcome on 
treatment of myocardial injury and failure. In addition to contributing to the purinergic field, the 
mechanisms by which the P2X4R confer cardioprotection touch upon many important and active 
areas in cardiobiology research, and continued progress in these fields, with synergistic 
developments in experimental and computational arenas, will enhance our understanding of  
and ability to manage and treat the complex disease that is heart failure.  
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 Appendix A 
 
The human P2X4R gene is located on the q arm of chromosome 12 and the mouse gene is 
located on chromosome 5. The gene contains 12 exons. Figure 1 demonstrates genetic 
targeting for exon 2-5 deletion to generate genetic knockouts and Table 1 provides primer 
sequences for genotyping.   
 
Figure 1: P2X4R Gene Structure and Targeting for knockout generation 
 
 
 
 
 
P2X4R OE mice  
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 aMHC Linker Forward GTC GAC TGA CTA ACT AGA AGC T 
P2X4 Linker Reverse CTG AGC TGG TAT CAC ATA ATC C 
  
P2X4floxed/floxed mice  
Lox gtF TTG CGA TTC AGA CGC CAA CT 
LoxgtR TCT ATT GCA GAC ATG CTA CC 
Frt gtF TTC TGC CTT GGG TTC AAA TC 
Frt gtR AGC CCC TTA CCC AGC TAC TC 
  
Hprttm1(cre)Mnn/J mice  
Transgene Forward GCG GTC TGG CAG TAA AAA CTA TC 
Transgene Reverse GTG AAA CAG CAT TGC TGT CAC TT 
Wildtype Forward  CAC AGT AGC TCT TCA GTC TGA TAA AA 
Wildtype Reverse TTT CTA TAG GAC TGA AAG ACT TGC TC 
 
Table 1. Primer Sequences for genotyping 
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